Aman U. Buzdar, MD

Peer-Reviewed Articles

1. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
2. Ingle JN, Kalari KR, Barman P, Shepherd LE, Ellis MJ, Goss PE, Buzdar AU, Robson ME, Cairns J, Carlson EE, Eyman Casey A, Hoskin TL, Goodnature BA, Haddad TC, Goetz MP, Weinshilboum RM, Wang L. Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenet Genomics 31(1):1-9, 2021. e-Pub 2021. PMID: 32649577.
3. Cairns J, Ingle JN, Dudenkov TM, Kalari KR, Carlson EE, Na J, Buzdar AU, Robson ME, Ellis MJ, Goss PE, Shepherd LE, Goodnature B, Goetz MP, Weinshilboum RM, Li H, Bari MG, Wang L. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight 5(16), 2020. e-Pub 2020. PMID: 32701512.
4. Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction between SLC38A7 and ALPPL2. Clin Pharmacol Ther 106(1):219-227, 2019. e-Pub 2019. PMID: 30648747.
5. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol 5(1):45-50, 2019. e-Pub 2019. PMID: 30193295.
6. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
7. Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Res Treat 164(1):189-199, 2017. e-Pub 2017. PMID: 28429243.
8. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol 28(5):1070-1077, 2017. e-Pub 2017. PMID: 28453704.
9. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol 35(10):1049-1060, 2017. e-Pub 2017. PMID: 28135148.
10. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res 23(6):1407-1413, 2017. e-Pub 2017. PMID: 27852698.
11. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res 23(6):1414-1421, 2017. e-Pub 2017. PMID: 28275168.
12. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. e-Pub 2017. PMID: 28327926.
13. Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 161(2):363-373, 2017. e-Pub 2017. PMID: 27866278.
14. Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat 159(1):109-18, 2016. e-Pub 2016. PMID: 27449492.
15. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer 56:85-92, 2016. e-Pub 2016. PMID: 26829011.
16. Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids 99(Pt A):32-8, 2015. e-Pub 2015. PMID: 25163006.
17. Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J. Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clin Cancer Res 21(12):2763-70, 2015. e-Pub 2015. PMID: 26078431.
18. Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE, Investigators T. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer 51(6):685-96, 2015. e-Pub 2015. PMID: 25752740.
19. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res 17(1):56, 2015. e-Pub 2015. PMID: 25888246.
20. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 2014. e-Pub 2014. PMID: 24721590.
21. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. e-Pub 2014. PMID: 24562447.
22. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK, Group investigators ACOSO. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 14(13):1317-25, 2013. e-Pub 2013. PMID: 24239210.
23. Buzdar AU. Combination endocrine treatments unproven in breast cancer. Lancet Oncol 14(10):917-8, 2013. e-Pub 2013. PMID: 23902873.
24. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. e-Pub 2013. PMID: 23562929.
25. Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat 140(2):253-62, 2013. e-Pub 2013. PMID: 23852223.
26. Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381(9883):2077-8, 2013. e-Pub 2013. PMID: 23769223.
27. Kelly CM, Buzdar AU. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer. Drugs 73(6):505-15, 2013. e-Pub 2013. PMID: 23605692.
28. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM. TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. Mol Endocrinol 27(4):657-70, 2013. e-Pub 2013. PMID: 23518928.
29. Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN. Mammographic Breast Density Response to Aromatase Inhibition. Clin Cancer Res 19(8):2144-53, 2013. e-Pub 2013. PMID: 23468058.
30. Goss PE, Smith Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, investigators T. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14(1):88-96, 2013. e-Pub 2013. PMID: 23234763.
31. Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA. Making Genuine Progress Against Metastatic Breast Cancer. J Clin Oncol 30(28):3448-51, 2012. e-Pub 2012. PMID: 22927527.
32. Buzdar A, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J, Houghton M, Zergebel C, Kimball B. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer 118(13):3244-53, 2012. e-Pub 2012. PMID: 22045595.
33. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we?. Ann Oncol 23(6):1378-86, 2012. e-Pub 2012. PMID: 22317766.
34. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: A follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in america. Cancer 118(10):2571-82, 2012. e-Pub 2012. PMID: 22045610.
35. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10):2603-14, 2012. e-Pub 2012. PMID: 22370716.
36. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 2012. e-Pub 2012. PMID: 21953213.
37. Kelly CM, Buzdar AU. Aromatase inhibitors in premenopausal breast cancer. Lancet Oncol 13(4):320-1, 2012. e-Pub 2012. PMID: 22265695.
38. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. J Clin Oncol 30(9):930-5, 2012. e-Pub 2012. PMID: 22331946.
39. Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S, group NO. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol 23(3):589-97, 2012. e-Pub 2012. PMID: 21633047.
40. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short -term biomarker modulation prevention study of Anastrozole in Women at increased risk for second primary breast cancer. Cancer Prev Res (Phila) 5(2):276-82, 2012. e-Pub 2012. PMID: 22102688.
41. Ewer MS, Yang M, Buzdar AU. Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits?. Clin Breast Cancer 12(1):1-3, 2012. e-Pub 2012. PMID: 22130035.
42. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current american joint committee on cancer staging system. J Clin Oncol 29(35):4654-61, 2011. e-Pub 2011. PMID: 22084362.
43. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. J Clin Oncol 29(32):4273-8, 2011. e-Pub 2011. PMID: 21990413.
44. Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J. Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. J Clin Oncol 29(32):4266-72, 2011. e-Pub 2011. PMID: 21990403.
45. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128(2):421-7, 2011. e-Pub 2011. PMID: 21553292.
46. Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J. Predictive algorithms for adjuvant therapy: TransATAC. Steroids 76(8):777-80, 2011. e-Pub 2011. PMID: 21470560.
47. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer 117(14):3268-75, 2011. e-Pub 2011. PMID: 21264831.
48. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol 29(15):1956-62, 2011. e-Pub 2011. PMID: 21482989.
49. Buzdar AU. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. Lancet Oncol 12(4):316-8, 2011. e-Pub 2011. PMID: 21429798.
50. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar AU, Martin PM, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics Clin Appl 5(3-4):193, 2011. e-Pub 2011. PMID: 21448880.
51. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy can Predict Patient Prognosis and Facilitate Treatment Planning. Ann Surg 253(3):572-9, 2011. e-Pub 2011. PMID: 21209588.
52. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators FT. 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply. Lancet Oncol 12(3):217, 2011. e-Pub 2011. PMID: 21376290.
53. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 2011. e-Pub 2011. PMID: 20740500.
54. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
55. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar AU, Martin PM, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics. e-Pub 2010. PMID: 20827732.
56. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348-3356, 2010. e-Pub 2010. PMID: 20564075.
57. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12):2884-9, 2010. e-Pub 2010. PMID: 20564395.
58. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28(11):1829-34, 2010. e-Pub 2010. PMID: 20212256.
59. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. Cancer Res 70(8):3278-86. e-Pub 2010. PMID: 20354183.
60. Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE, Mamounas EP, Wolmark N. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 10(1):81-6, 2010. e-Pub 2010. PMID: 20133263.
61. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2010. e-Pub 2010. PMID: 20052721.
62. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 70(1):319-28, 2010. e-Pub 2010. PMID: 20048079.
63. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. J Clin Oncol 28(1):92-8, 2010. e-Pub 2010. PMID: 19933921.
64. Collaborative Group EBCT. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 41:162-77, 2010. e-Pub 2010. PMID: 20956824.
65. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. Clin Cancer Res, 2009. e-Pub 2009. PMID: 19920100.
66. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. J Clin Oncol, 2009. e-Pub 2009. PMID: 19949017.
67. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18 Suppl 2:S1-11, 2009. e-Pub 2009. PMID: 19712865.
68. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated with Paclitaxel. J Pain, 2009. e-Pub 2009. PMID: 19595634.
69. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2009. e-Pub 2009. PMID: 18581139.
70. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer. Clin Breast Cancer 8(6):516-21, 2008. e-Pub 2008. PMID: 19073507.
71. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891-8, 2008. e-Pub 2008. PMID: 18725649.
72. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072-7, 2008. e-Pub 2008. PMID: 18757321.
73. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res 68(16):6477-81, 2008. e-Pub 2008. PMID: 18701468.
74. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. J Natl Cancer Inst, 2008. e-Pub 2008. PMID: 18695137.
75. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol, 2008. e-Pub 2008. PMID: 18703382.
76. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 99(1):68-71, 2008. e-Pub 2008. PMID: 18560403.
77. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020-5, 2008. e-Pub 2008. PMID: 18667396.
78. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664-70, 2008. e-Pub 2008. PMID: 18316794.
79. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26(2):246-52, 2008. e-Pub 2008.
80. Boughey JC, Buzdar AU, Hunt KK. Recent advances in the hormonal treatment of breast cancer. Curr Probl Surg 45(1):13-55, 2008. e-Pub 2008.
81. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol. e-Pub 2008.
82. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112(S3):700-9, 2007. e-Pub 2007.
83. Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference. Cancer 112(S3)(3 Suppl):673-8, 2007. e-Pub 2007. PMID: 18072254.
84. Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 9(6):R87, 2007. e-Pub 2007. PMID: 18086299.
85. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 25(31):4967-73, 2007. e-Pub 2007. PMID: 17971595.
86. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. e-Pub 2007. PMID: 17998286.
87. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-22, 2007. e-Pub 2007. PMID: 17785706.
88. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110(6):1195-200, 2007. e-Pub 2007.
89. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN. Trends for inflammatory breast cancer: is survival improving?. Oncologist 12(8):904-12, 2007. e-Pub 2007. PMID: 17766649.
90. Buzdar AU. Adjuvant chemotherapy for high-risk operable breast cancer. J Clin Oncol 25(13):1642-4, 2007. e-Pub 2007. PMID: 17404366.
91. Buzdar AU. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. J Clin Oncol 25(15):2147-8, 2007. e-Pub 2007.
92. Mazouni C, Kau SW, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol, 2007. e-Pub 2007. PMID: 17293601.
93. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109:496-501, 2007. e-Pub 2007. PMID: 17149760.
94. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-33, 2007. e-Pub 2007. PMID: 17200359.
95. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 13:72-5, 2007. e-Pub 2007. PMID: 17214797.
96. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13:1443-9, 2006. e-Pub 2006. PMID: 17028770.
97. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-44, 2006. e-Pub 2006. PMID: 16896004.
98. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 244:464-70, 2006. e-Pub 2006. PMID: 16926572.
99. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 107:1248-54, 2006. e-Pub 2006. PMID: 16862596.
100. Arimidex T, Tamoxifen, Trialists' Group AOIC, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet 7:633-42, 2006. e-Pub 2006. PMID: 16887480.
101. Buzdar AU, Guastalla JP, Nabholtz JM, Cuzick J, Group AT. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 107:472-80, 2006. e-Pub 2006. PMID: 16804925.
102. Buzdar AU, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 22:1575-85, 2006. e-Pub 2006. PMID: 16870082.
103. Buchholz TA, Strom EA, Oswald MJ, Perkins GH, Oh J, Domain D, Yu TK, Woodward WA, Tereffe W, Singletary SE, Thomas E, Buzdar AU, Hortobagyi GN, McNeese MD. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys 65:1155-60, 2006. e-Pub 2006. PMID: 16750325.
104. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary carcinoma: follow-up at 12 years. Cancer 106:2327-36, 2006. e-Pub 2006. PMID: 16639731.
105. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Camparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106:2095-103, 2006. e-Pub 2006. PMID: 16598749.
106. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106:1000-6, 2006. e-Pub 2006. PMID: 16444747.
107. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-44, 2006. e-Pub 2006. PMID: 16505422.
108. Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 12:1037s-1048s, 2006. e-Pub 2006. PMID: 16467122.
109. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243:257-64, 2006. e-Pub 2006. PMID: 16432360.
110. Yamaya H, Saeki M, Yoshida K, Shibata J, Yano S, Sato Y, Takao A, Shindo T, Buzdar AU, Nagayama S. Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor. Drug Metab Dispos 34:331-8, 2006. e-Pub 2006. PMID: 16299166.
111. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res 12:997s-1000s, 2006. e-Pub 2006. PMID: 16467115.
112. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. Cancer 104:2359-64, 2005. e-Pub 2005. PMID: 16270318.
113. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304-11, 2005. e-Pub 2005. PMID: 16361629.
114. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331-9, 2005. e-Pub 2005. PMID: 16293864.
115. Buzdar AU, Cuzick J. Optimum use of aromastase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol 23:8544-6, 2005. e-Pub 2005. PMID: 16293888.
116. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metstases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23:7098-104, 2005. e-Pub 2005. PMID: 16192593.
117. Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T, Nagayama S, Buzdar AU. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. J Clin Pharm Ther 30:459-70, 2005. e-Pub 2005. PMID: 16164493.
118. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 104:1158-71, 2005. e-Pub 2005. PMID: 16047352.
119. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-92, 2005. e-Pub 2005. PMID: 16087943.
120. Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer 104:229-35, 2005. e-Pub 2005. PMID: 15937910.
121. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62:351-7, 2005. e-Pub 2005. PMID: 15890574.
122. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault RL, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103:2466-72, 2005. e-Pub 2005. PMID: 15852360.
123. Buzdar AU, Inbrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-85, 2005. e-Pub 2005. PMID: 15738535.
124. Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens?. J Steroid Biochem Mol Biol 93:237-47, 2005. e-Pub 2005. PMID: 15860266.
125. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-8, 2005. e-Pub 2005. PMID: 15625359.
126. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lonning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res 11(2 Pt 2):861s-4s, 2005. e-Pub 2005. PMID: 15701878.
127. Howell A, Cuzick J, Baum M, Buzdar AU, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-2, 2005. e-Pub 2005. PMID: 15639680.
128. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res 11(1):315-22, 2005. e-Pub 2005. PMID: 15671561.
129. Buzdar A, Macahilig C. How rapidly do oncologists respond to clinical trial data?. Oncologist 10(1):15-21, 2005. e-Pub 2005. PMID: 15632249.
130. Buzdar AU. TAS-108: a novel steroidal antiestrogen. Clinical Cancer Research 11(2):906s-908s, 2005. e-Pub 2005.
131. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA. Postmacestomy radiation improves local-regional control and survival for selected patients with local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22:4691-9, 2004. e-Pub 2004. PMID: 15570071.
132. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 96:1676-81, 2004. e-Pub 2004. PMID: 15547180.
133. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio K, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101:1760-6, 2004. e-Pub 2004. PMID: 15386311.
134. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. e-Pub 2004. PMID: 15378497.
135. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 10:6215-21, 2004. e-Pub 2004. PMID: 15448010.
136. Resetkova E, Gonzalez-Angulo AM, Sneige N, Mcdonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer 101:913-7, 2004. e-Pub 2004. PMID: 15329897.
137. Blakely LJ, Buzdar A, Chang HY, Frye D, Theriault R, Valero V, Rivera E, Booser D, Kuritani J, Tsuda M. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res 10(16):5425-31, 2004. e-Pub 2004. PMID: 15328180.
138. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101(3):466-75, 2004. e-Pub 2004. PMID: 15274059.
139. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59(5):1337-42, 2004. e-Pub 2004. PMID: 15275718.
140. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101(2):258-63, 2004. e-Pub 2004. PMID: 15241821.
141. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 101(1):51-7, 2004. e-Pub 2004. PMID: 15221988.
142. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22(12):2294-302, 2004. e-Pub 2004. PMID: 15197190.
143. Buzdar AU, Vergote I, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J 10(3):211-7, 2004. e-Pub 2004. PMID: 15125747.
144. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 59(1):138-45, 2004. e-Pub 2004. PMID: 15093909.
145. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100(7):1365-73, 2004. e-Pub 2004. PMID: 15042669.
146. Buzdar AU. Preoperative chemotherapy for breast cancer. Clin Adv Hematol Oncol 2:212-5, 2004. e-Pub 2004. PMID: 16163183.
147. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 4(6):415-9, 2004. e-Pub 2004. PMID: 15023242.
148. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100(3):499-506, 2004. e-Pub 2004. PMID: 14745865.
149. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100(3):465-9, 2004. e-Pub 2004. PMID: 14745861.
150. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving?. Cancer 100(1):44-52, 2004. e-Pub 2004. PMID: 14692023.
151. Buzdar AU. Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar. Drugs 64:1848-9, 2004. e-Pub 2004. PMID: 15301566.
152. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9):1802-10, 2003. e-Pub 2003. PMID: 14584060.
153. Simons WR, Jones D, Buzdar A. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther 25(11):2972-87, 2003. e-Pub 2003. PMID: 14693319.
154. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 57(2):336-44, 2003. e-Pub 2003. PMID: 12957243.
155. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, Buzdar AU, Buchholz TA. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys 57(2):327-35, 2003. e-Pub 2003. PMID: 12957242.
156. Buzdar AU. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. J Steroid Biochem Mol Biol 86(3-5):399-403, 2003. e-Pub 2003. PMID: 14623537.
157. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39(12):1684-9, 2003. e-Pub 2003. PMID: 12888362.
158. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, 2003. e-Pub 2003. PMID: 12784330.
159. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer 97(11):2716-23, 2003. e-Pub 2003. PMID: 12767083.
160. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97(7):1758-65, 2003. e-Pub 2003. PMID: 12655533.
161. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21(6):1007-14, 2003. e-Pub 2003. PMID: 12637464.
162. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105-18, 2003. e-Pub 2003. PMID: 12611463.
163. Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys 53(5):1225-33, 2002. e-Pub 2002. PMID: 12128124.
164. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386-95, 2002. e-Pub 2002. PMID: 12177098.
165. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53(4):880-8, 2002. e-Pub 2002. PMID: 12095553.
166. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25(3):235-7, 2002. e-Pub 2002. PMID: 12040279.
167. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8(5):1073-9, 2002. e-Pub 2002. PMID: 12006521.
168. Buzdar A, Hayes D, El-Khoudary A, Yan S, Lonning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73(2):161-75, 2002. e-Pub 2002. PMID: 12088118.
169. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 9(3):228-34, 2002. e-Pub 2002. PMID: 11923128.
170. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20(1):17-23, 2002. e-Pub 2002. PMID: 11773149.
171. Buchholz TA, Tucker SL, Katz A, McNeese MD, Strom EA, Perkins GH, Buzdar AU, Kuerer HM, Hunt KK, Singletary SE, Sahin AA, Thames HD, Meric F, Masullo L, Hortobagyi GN. Factors predictive for local-regional recurrence after neoadjuvant chemotherapy and mastectomy: implications for radiation treatment. The American Journal of Oncology Review 1(1):13-16, 2002. e-Pub 2002.
172. Trialists’ Group TA. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002. e-Pub 2002.
173. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 8(1):2-9, 2002. e-Pub 2002. PMID: 11856154.
174. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 182(6):601-8, 2001. e-Pub 2001. PMID: 11839324.
175. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247-58, 2001. e-Pub 2001. PMID: 11745278.
176. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 92(10):2523-8, 2001. e-Pub 2001. PMID: 11745185.
177. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92(7):1775-82, 2001. e-Pub 2001. PMID: 11745249.
178. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 7(5):413-20, 2001. e-Pub 2001. PMID: 11693900.
179. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19(14):3357-66, 2001. e-Pub 2001. PMID: 11454883.
180. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 8(5):425-31, 2001. e-Pub 2001. PMID: 11407517.
181. Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 19(7):2002-9, 2001. e-Pub 2001. PMID: 11283133.
182. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 19(8):2240-6, 2001. e-Pub 2001. PMID: 11304777.
183. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19(3):628-33, 2001. e-Pub 2001. PMID: 11157012.
184. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91(4):664-71, 2001. e-Pub 2001. PMID: 11241232.
185. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171-7, 2001. e-Pub 2001. PMID: 11692142.
186. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, rd, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-66, 2001. e-Pub 2001. PMID: 11458813.
187. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89(11):2195-201, 2000. e-Pub 2000. PMID: 11147589.
188. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol 11(12):1597-601, 2000. e-Pub 2000. PMID: 11205469.
189. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758-67, 2000. e-Pub 2000. PMID: 11078488.
190. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64(2):157-63, 2000. e-Pub 2000. PMID: 11194451.
191. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18(20):3480-6, 2000. e-Pub 2000. PMID: 11032588.
192. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, Buzdar AU, Singletary SE. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol 7(8):581-7, 2000. e-Pub 2000. PMID: 11005556.
193. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, Hortobagyi G, Buzdar AU, Theriault R, Singletary SE, McNeese MD. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18(15):2817-27, 2000. e-Pub 2000. PMID: 10920129.
194. Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, McNeese MD. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 47(5):1191-200, 2000. e-Pub 2000. PMID: 10889372.
195. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer. Breast J 6(4):242-246, 2000. e-Pub 2000. PMID: 11348372.
196. Vlastos G, Fornage BD, Mirza NQ, Bedi D, Lenert JT, Winchester DJ, Tolley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Buzdar AU, Singletary SE. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg 179(6):446-52, 2000. e-Pub 2000. PMID: 11004328.
197. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, Asmar L, Frye D, McNeese MD, Hortobagyi GN. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 88(9):2054-60, 2000. e-Pub 2000. PMID: 10813717.
198. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 23(2):117-21, 2000. e-Pub 2000. PMID: 10776969.
199. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology 58(3):185-90, 2000. e-Pub 2000. PMID: 10765118.
200. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, Buzdar AU, Singletary SE. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer 88(6):1417-24, 2000. e-Pub 2000. PMID: 10717625.
201. Kushwaha AC, Whitman GJ, Stelling CB, Cristofanilli M, Buzdar AU. Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. AJR Am J Roentgenol 174(2):535-8, 2000. e-Pub 2000. PMID: 10658737.
202. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant 14(1):32-41, 2000. e-Pub 2000. PMID: 10693633.
203. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82(3):529-34, 2000. e-Pub 2000. PMID: 10682660.
204. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92(3):225-33, 2000. e-Pub 2000. PMID: 10655439.
205. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281-3, 2000. e-Pub 2000. PMID: 10675076.
206. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 6(8):762-7, 1999. e-Pub 1999. PMID: 10622504.
207. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17(11):3412-7, 1999. e-Pub 1999. PMID: 10550135.
208. Robertson JF, Howell A, Buzdar A, von Euler M, Lee D. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 58(2):157-62, 1999. e-Pub 1999. PMID: 10674881.
209. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, rd, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-7, 1999. e-Pub 1999. PMID: 10506711.
210. Buchholz TA, Hunt KK, Amosson CM, Tucker SL, Strom EA, McNeese MD, Buzdar AU, Singletary SE, Hortobagyi GN. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am 5(3):159-64, 1999. e-Pub 1999. PMID: 10367172.
211. Knoche AJ, Michaud LB, Buzdar AU. Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience. Breast J 5(3):176-181, 1999. e-Pub 1999. PMID: 11348281.
212. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17(5):1425-34, 1999. e-Pub 1999. PMID: 10334527.
213. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 10(4):403-11, 1999. e-Pub 1999. PMID: 10370782.
214. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 17(3):855-61, 1999. e-Pub 1999. PMID: 10071276.
215. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460-9, 1999. e-Pub 1999. PMID: 10080586.
216. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485-93, 1999. e-Pub 1999. PMID: 10080589.
217. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85(1):104-11, 1999. e-Pub 1999. PMID: 9921981.
218. Ibrahim NK, Hortobagyi GN, Ewer M, Ali MK, Asmar L, Theriault RL, Fraschini G, Frye DK, Buzdar AU. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 43(6):471-8, 1999. e-Pub 1999. PMID: 10321507.
219. Rivera E, Fraschini G, Esparza-Guerra L, Asmar L, Booser DJ, Buzdar AU, Theriault RL, Carrasco CH, Hortobagyi GN. Frontline arterial infusion chemotherapy for hepatic metastases in breast cancer patients. Cancer Therapeutics 2:44-49, 1999. e-Pub 1999.
220. Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, Buzdar AU, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 5(8):673-80, 1998. e-Pub 1998. PMID: 9869512.
221. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol 16(12):3731-5, 1998. e-Pub 1998. PMID: 9850015.
222. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176(6):502-9, 1998. e-Pub 1998. PMID: 9926779.
223. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83(6):1142-52, 1998. e-Pub 1998. PMID: 9740079.
224. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 4(4):230-6, 1998. e-Pub 1998. PMID: 9689981.
225. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82(12):2366-72, 1998. e-Pub 1998. PMID: 9635529.
226. Diaz-Canton EA, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, Buzdar AU, Hortobagyi GN. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol 9(4):413-8, 1998. e-Pub 1998. PMID: 9636832.
227. Collaborative Group EBCT. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998. e-Pub 1998.
228. Collaborative Group EBCT. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998. e-Pub 1998.
229. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 80(12):2240-9, 1997. e-Pub 1997. PMID: 9404700.
230. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15(10):3171-7, 1997. e-Pub 1997. PMID: 9336352.
231. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Buzdar AU, Podoloff DA. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging 21(5):332-6, 1997. e-Pub 1997. PMID: 9316752.
232. Fleming RY, Asmar L, Buzdar AU, McNeese MD, Ames FC, Ross MI, Singletary SE. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 4(6):452-61, 1997. e-Pub 1997. PMID: 9309333.
233. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3(9):1565-9, 1997. e-Pub 1997. PMID: 9815844.
234. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40(4):321-9, 1997. e-Pub 1997. PMID: 9225950.
235. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A, Study Group FTA. A Phase III Trial Comparing Anastrozole (1 and 10 Milligrams), a Potent and Selective Aromatase Inhibitor, with Megestrol Acetate in Postmenopausal Women with Advanced Breast Carcinoma. Cancer 79:730-739, 1997. e-Pub 1997.
236. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14(10):2713-21, 1996. e-Pub 1996. PMID: 8874332.
237. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 14(10):2722-30, 1996. e-Pub 1996. PMID: 8874333.
238. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14(8):2197-205, 1996. e-Pub 1996. PMID: 8708708.
239. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff DA. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 11(4):235-45, 1996. e-Pub 1996. PMID: 10851543.
240. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14(7):2000-11, 1996. e-Pub 1996. PMID: 8683230.
241. Study Group MTC, Buzdar AU, Smith R, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 77(12):2503-2513, 1996. e-Pub 1996.
242. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 156(8):882-8, 1996. e-Pub 1996. PMID: 8774207.
243. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13(12):2886-94, 1995. e-Pub 1995. PMID: 8523051.
244. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res 1(7):691-7, 1995. e-Pub 1995. PMID: 9816034.
245. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 55(14):3060-7, 1995. e-Pub 1995. PMID: 7606728.
246. Collaborator Group EBCT. Effects of Radiotherapy and Surgery in Early Breast Cancer. An Overview of the Randomized Trials. N Engl J Med 333(22):1444-1455, 1995. e-Pub 1995.
247. Mora EM, Singletary SE, Buzdar AU, Johnston DA. Aggressive Therapy For Locoregional Recurrence After Mastectomy In Stage II and III Breast Cancer Patients. Ann Surg Oncol 3(2):162-168, 1995. e-Pub 1995.
248. Buzdar AU, Esparza L, Natale R, Cody R, Calzone K, Benson AB, rd, Sheehan T, Berry W. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol 17(5):417-21, 1994. e-Pub 1994. PMID: 8092114.
249. Hortobagyi GN, Holmes FA, Theriault RL, Buzdar AU. Use of Taxol (paclitaxel) in breast cancer. Oncology 51 Suppl 1:29-32, 1994. e-Pub 1994. PMID: 7970507.
250. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73(8):2157-67, 1994. e-Pub 1994. PMID: 8156520.
251. Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol 12(1):50-4, 1994. e-Pub 1994. PMID: 8270984.
252. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 33(4):313-6, 1994. e-Pub 1994. PMID: 8281625.
253. Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs 12(3):235-41, 1994. e-Pub 1994. PMID: 7896543.
254. Holmes FA, Buzdar AU, S-W K, Fraschini G, Ames FC, McNeese MD, Hortobagyi GN. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): The M. D. Anderson experience. Breast Dis 7:7-20, 1994. e-Pub 1994.
255. Yang DJ, Li C, Kuang LR, Price JE, Buzdar AU, Tansey W, Cherif A, Gretzer M, Kim EE, Wallace S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 55(1):53-67, 1994. e-Pub 1994. PMID: 8015349.
256. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120(1):18-25, 1994. e-Pub 1994. PMID: 8250452.
257. Buzdar AU, Kau SW, Smith TL, Ames F, Singletary E, Strom E, McNeese M, Hortobagyi GN. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 71(11):3680-4, 1993. e-Pub 1993. PMID: 8490917.
258. Theriault RL, Stallings CB, Buzdar AU. Pregnancy and breast cancer: clinical and legal issues. Am J Clin Oncol 15(6):535-9, 1992. e-Pub 1992. PMID: 1333169.
259. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol 10(10):1540-6, 1992. e-Pub 1992. PMID: 1403033.
260. Jaiyesimi IA, Buzdar AU. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. Am J Clin Oncol 15(2):180-3, 1992. e-Pub 1992. PMID: 1313203.
261. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69(2):448-52, 1992. e-Pub 1992. PMID: 1728373.
262. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 69(2):476-81, 1992. e-Pub 1992. PMID: 1728377.
263. Simmons JR, Buzdar AU, Ota DM, Marts K, Hortobagyi GN. Complications associated with indwelling catheters. Med and Pediat Oncol 20:22-25, 1992. e-Pub 1992.
264. Hortobagyi GN, Buzdar AU. Ten-year survival after chemotherapy for high risk primary and metastatic breast carcinoma. Cancer Invest 10:12-14, 1992. e-Pub 1992.
265. Early Breast Cancer Trialists' Collaborative Group - Buzdar AU, Smith T, et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. The Lancet 339(8784):1-15, 71-85, 1992. e-Pub 1992.
266. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83(24):1797-805, 1991. e-Pub 1991. PMID: 1683908.
267. Fraschini G, Holmes FA, Esparza L, Theriault RL, Buzdar AU, Hortobagyi GN. Phase I-II study of high-dose etoposide in patients with refractory breast cancer. Invest New Drugs 9(4):365-7, 1991. e-Pub 1991. PMID: 1804815.
268. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 18(3):165-70, 1991. e-Pub 1991. PMID: 1756259.
269. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 32(7):1326-32, 1991. e-Pub 1991. PMID: 2066785.
270. Wallerstein R, Jr, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8(11):1782-8, 1990. e-Pub 1990. PMID: 2121909.
271. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8(7):1207-16, 1990. e-Pub 1990. PMID: 2358837.
272. Holmes FA, Fritsche HA, Loewy JW, Geitner AM, Sutton RC, Buzdar AU, Hortobagyi GN. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol 8(6):1025-35, 1990. e-Pub 1990. PMID: 2189952.
273. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65(4):847-50, 1990. e-Pub 1990. PMID: 2297653.
274. Buzdar AU, McNeese MD, Hortobagyi GN, Smith TL, Kau S, Fraschini G, Hug V, Ellerbroek N, Holmes FA, Ames F, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?. Cancer 65(3):394-9, 1990. e-Pub 1990. PMID: 2297630.
275. Theriault RL, Buzdar AU. Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy. Med Pediatr Oncol 18(1):77-80, 1990. e-Pub 1990. PMID: 2152960.
276. Vanek N, Hortobagyi GN, Buzdar AU. Radiotherapy enhances the toxicity of aminoglutethimide. Med Pediatr Oncol 18(2):162-4, 1990. e-Pub 1990. PMID: 2154663.
277. Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G, Lichtiger B. Elliptinium acetate in metastatic breast cancer--a phase II study. Oncology 47(2):101-4, 1990. e-Pub 1990. PMID: 2314820.
278. Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 27(2):94-100, 1990. e-Pub 1990. PMID: 2249339.
279. Ang PT, Buzdar AU, Smith TL, Kau S, Hortobagyi GN. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7(11):1677-84, 1989. e-Pub 1989. PMID: 2809682.
280. Patel HZ, nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 64(8):1583-5, 1989. e-Pub 1989. PMID: 2676137.
281. Thoms WW, Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17(4):739-45, 1989. e-Pub 1989. PMID: 2487034.
282. Hortobagyi GN, Hug V, Buzdar AU, Kau SW, Holmes FA, Fritsche HA. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer 64(5):1002-6, 1989. e-Pub 1989. PMID: 2527085.
283. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 7(8):1129-36, 1989. e-Pub 1989. PMID: 2569033.
284. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12(2):123-8, 1989. e-Pub 1989. PMID: 2705401.
285. Theriault RL, Hortobagyi GN, Fritsche HA, Frye D, Martinez R, Buzdar AU. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer 63(5):828-35, 1989. e-Pub 1989. PMID: 2914290.
286. Chu PS, Buzdar AU, Hortobagyi GN. Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat 13(2):117-21, 1989. e-Pub 1989. PMID: 2659103.
287. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124(1):21-5, 1989. e-Pub 1989. PMID: 2910244.
288. Ro J, Fraschini G, Frye D, Buzdar A, Hortobagyi G. Reutilization of doxorubicin in patients with progressive metastatic breast cancer. Intl J Exp Clin Chemother 2:234-238, 1989. e-Pub 1989.
289. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1):37-45, 1989. e-Pub 1989. PMID: 2910423.
290. Theriault RL, Hortobagyi GN, Kau SW, Holmes FA, Hug V, Fraschini G, Jabboury K, Buzdar AU. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer 62(10):2105-10, 1988. e-Pub 1988. PMID: 3179923.
291. Buzdar AU, Hortobagyi GN, Smith TL, Kau S, Marcus C, Holmes FA, Hug V, Fraschini G, Ames FC, Martin RG. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer 62(10):2098-104, 1988. e-Pub 1988. PMID: 3179922.
292. Hortobagyi GN, Buzdar AU. Management of locally advanced breast cancer. Am J Clin Oncol 11(5):597-601, 1988. e-Pub 1988. PMID: 2845771.
293. Fraschini G, Holmes FA, Buzdar AU, Hug V, Hortobagyi GN. Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer. Am J Clin Oncol 11(4):448-50, 1988. e-Pub 1988. PMID: 3407623.
294. Skinner WL, Buzdar AU, Libshitz HI. Massive osteolysis of the right clavicle developing after radiation therapy. Jama 260(3):375-6, 1988. e-Pub 1988. PMID: 3379746.
295. Berte E, Buzdar AU, Smith TL, Hortobagyi GN. Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol 11(2):114-8, 1988. e-Pub 1988. PMID: 3128945.
296. Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol 11(1):34-8, 1988. e-Pub 1988. PMID: 3277374.
297. Early Breast Cancer Trialists' Collaborative Group Henderson IC, Mouridsen H, Abe O, Abeloff M, Ahmann D, Andersen K, Baum M, Bianco AR, Boccardo F, Bonadonna G, Buyse M, Buzdar A, Carbone P, Carpenter J, Chlebowski R, Collins, Cooper R, Crowley J, Cuzick J, Day N, Delozier T, de Schryver A, Dubois J, Durrant K, Fisher B, Forbes J, Forrest P, Gelber R, Gelman R, Glick J, Godwin J, Goldhirsch A, Gray R, Hayward J, Hill C, Howell A, Hubay C, Jakesz R, Kaufmann M, Kissin M, L-G L, Lippman M, Margreiter R, Mauriac L, McCardle C, Morrison M, Naja A, Nissen-Meyer R, Nomura Y, Oates GD, Osborne K, Palshof T, Peek U, Peto R, Pritchard K, Redmond C, Repelaer van Driel O, Ribeiro G, Rubens R, Rutqvist L, Ryden S, Scanlon E, Scheurlen H, Semiglazov V, Senanayake F, Senn HJ, Simon R, Smith C, Soderberg M, Spittle M, Stewart H, Swindell R, Tormey D, Valagussa P, van Dongen J, Wallgren A, Wittes R, Wolmark N, Wood W. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An Overview of 61 Randomized Trials among 28,896 Women. N Engl J Med 319(26):1681-1692, 1988. e-Pub 1988.
298. Buzdar AU, Yap HY, Esparza L, Holmes F, Fraschini G, Hug V, Hortobagyi GN. A comparative randomized trial of doxorubicin and cyclophosphamide in combination with fluorouracil (FAC) or etoposide (EAC) in metastatic breast cancer. Intl J Exp & Clin Chemother 1:48-55, 1988. e-Pub 1988.
299. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45(5):344-5, 1988. e-Pub 1988. PMID: 3412740.
300. Hortobagyi GN, Frye D, Holmes FA, Hug V, Fraschini G, Buzdar AU. Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep 71(12):1193-6, 1987. e-Pub 1987. PMID: 3690529.
301. Hortobagyi GN, Buzdar AU, Frye D, Hug V, Fraschini G, Ames FC, Montague E, Gutterman JU, Martin RG. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer 60(11):2596-604, 1987. e-Pub 1987. PMID: 3315173.
302. Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, Buzdar A, Montague E. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 10(5):396-403, 1987. e-Pub 1987. PMID: 3310604.
303. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 10(5):387-95, 1987. e-Pub 1987. PMID: 3310603.
304. Fraschini G, Yap HY, Mann G, Buzdar AU, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer 60(8):1724-8, 1987. e-Pub 1987. PMID: 3652000.
305. Ro J, Buzdar AU, Esparza L, Hortobagyi GN. Phase II study of peplomycin in advanced breast carcinoma. Cancer Treat Rep 71(7-8):777-8, 1987. e-Pub 1987. PMID: 2440571.
306. Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer 59(12):1992-9, 1987. e-Pub 1987. PMID: 3567861.
307. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5(5):773-82, 1987. e-Pub 1987. PMID: 3106583.
308. Ventura GJ, Buzdar AU, Kau S, Lichtiger B, Hortobagyi GN. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. Cancer Treat Rep 71(4):411-3, 1987. e-Pub 1987. PMID: 3548958.
309. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5(3):354-64, 1987. e-Pub 1987. PMID: 3819804.
310. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 5(2):178-84, 1987. e-Pub 1987. PMID: 3543241.
311. Kramer A, Buzdar AU. Inflammatory breast carcinoma. Am J Clin Oncol 9(6):541-3, 1986. e-Pub 1986. PMID: 3024479.
312. Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. Jama 256(21):2988-90, 1986. e-Pub 1986. PMID: 3773217.
313. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58(12):2589-93, 1986. e-Pub 1986. PMID: 3779609.
314. Theriault RL, Hortobagyi GN, Buzdar AU, Levy HB, Hersh EM. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep 70(11):1341-2, 1986. e-Pub 1986. PMID: 3768878.
315. Janjan NA, McNeese MD, Buzdar AU, Montague ED, Oswald MJ. Management of locoregional recurrent breast cancer. Cancer 58(7):1552-6, 1986. e-Pub 1986. PMID: 3755648.
316. Polyzos A, Buzdar AU. Complete remission with combination chemotherapy in metastatic breast carcinoma. Am J Clin Oncol 9(4):361-3, 1986. e-Pub 1986. PMID: 3751975.
317. Herring MK, Buzdar AU, Smith TL, Hortobagyi GN, Blumenschein GR. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol 9(3):269-75, 1986. e-Pub 1986. PMID: 3755282.
318. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46(5):2578-81, 1986. e-Pub 1986. PMID: 3697997.
319. Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol 18(2):157-61, 1986. e-Pub 1986. PMID: 3791560.
320. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57(1):40-3, 1986. e-Pub 1986. PMID: 3940620.
321. Casimir MT, Buzdar AU, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology 43(4):205-7, 1986. e-Pub 1986. PMID: 3755230.
322. Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer 56(10):2381-4, 1985. e-Pub 1985. PMID: 4042070.
323. Mann GB, Hortobagyi GN, Buzdar AU, Yap HY, Valdivieso M. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer 56(6):1320-4, 1985. e-Pub 1985. PMID: 4027872.
324. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep 69(9):1003-4, 1985. e-Pub 1985. PMID: 4028032.
325. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer 56(2):225-9, 1985. e-Pub 1985. PMID: 4005794.
326. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55(12):2761-5, 1985. e-Pub 1985. PMID: 3922612.
327. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol 8(2):134-41, 1985. e-Pub 1985. PMID: 3841746.
328. Yau JC, Yap YY, Buzdar AU, Hortobagyi GN, Bodey GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer 55(2):337-40, 1985. e-Pub 1985. PMID: 3880657.
329. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55(2):341-6, 1985. e-Pub 1985. PMID: 3965092.
330. Feldman LD, Buzdar AU, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology 42(5):273-4, 1985. e-Pub 1985. PMID: 4034143.
331. J-M M, J-M B, Goodman A, Alberici GF, Caille P, Troalen F, Rouesse J, Bohuon C, Gralla RJ, Einzig AI, Buzdar AU. Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium Acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis. J Clin Oncol 3:735-740, 1985. e-Pub 1985.
332. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 5(3):321-6, 1985. e-Pub 1985. PMID: 3161565.
333. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol 20(11):1353-61, 1984. e-Pub 1984. PMID: 6548710.
334. Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin S, Buzdar A, Montague E. Using a database of protocol studies to evaluate therapy: a breast cancer example. Stat Med 3(4):333-9, 1984. e-Pub 1984. PMID: 6528133.
335. Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol 26(3):205-7, 1984. e-Pub 1984. PMID: 6610802.
336. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep 68(7-8):1039-41, 1984. e-Pub 1984. PMID: 6547638.
337. Finnerty NA, Buzdar AU, Blumenschein GR. Radiation-induced breast cancer. Arch Intern Med 144(6):1217-9, 1984. e-Pub 1984. PMID: 6732380.
338. Pinnamaneni K, Yap HY, Buzdar AU, Distefano A, Blumenschein GR. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer 53(9):1841-4, 1984. e-Pub 1984. PMID: 6546706.
339. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer 53(9):1836-40, 1984. e-Pub 1984. PMID: 6231092.
340. Chawla SP, Buzdar AU, Hortobagyi GN, Blumenschein GR. Tumor-associated fever in breast cancer. Cancer 53(7):1596-9, 1984. e-Pub 1984. PMID: 6697296.
341. Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer 53(3):384-9, 1984. e-Pub 1984. PMID: 6362814.
342. Buzdar AU, Blumenschein GR, Montague ED, Hortobagyi GN, Yap HY, Pinnamaneni K, Marcus CE, Smith TL. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol 7(1):45-50, 1984. e-Pub 1984. PMID: 6364779.
343. Lippman ME, Buzdar AU, Tormey DC, McGuire WL. Combining endocrine and chemotherapy - any true benefits?. Breast Cancer Res Treat 4:251-259, 1984. e-Pub 1984.
344. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1(12):776-86, 1983. e-Pub 1983. PMID: 6668494.
345. Harkins LA, Yap HY, Buzdar AU, Blumenschein GR. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. Cancer 52(7):1308-11, 1983. e-Pub 1983. PMID: 6883292.
346. Ali MK, Buzdar AU, Ewer MS, Cheng RS, Haynie TP. Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer. J Surg Oncol 23(3):212-6, 1983. e-Pub 1983. PMID: 6865442.
347. Hall SM, Buzdar AU, Blumenschein GR. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer 52(1):180-4, 1983. e-Pub 1983. PMID: 6850542.
348. Hortobagyi GN, Spanos W, Montague ED, Buzdar AU, Yap HY, Blumenschein GR. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys 9(5):643-50, 1983. e-Pub 1983. PMID: 6343312.
349. DeMartini AL, Buzdar AU, Blumenschein GR. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. J Surg Oncol 23(1):32-4, 1983. e-Pub 1983. PMID: 6687746.
350. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. Jama 249(14):1881-6, 1983. e-Pub 1983. PMID: 6834584.
351. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F. Multimodal treatment of locoregionally advanced breast cancer. Cancer 51(5):763-8, 1983. e-Pub 1983. PMID: 6687377.
352. Hortobagyi GN, Yap HY, Blumenschein GR, Buzdar AU, Barnes BC, Legha SS, Wiseman CL. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer 51(5):769-72, 1983. e-Pub 1983. PMID: 6600415.
353. Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143(2):237-40, 1983. e-Pub 1983. PMID: 6824391.
354. Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Mesures repetees de l' antigene carcinoembryonnaire plasmatique dans le traitement des cancers due sein metastases. JAMA (ed. Francaise) 7:619-620, 1983. e-Pub 1983.
355. Buzdar AU, Powell KC, Legha SS, Blumenschein GR. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer 50(9):1708-12, 1982. e-Pub 1982. PMID: 6180820.
356. Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol 5(5):511-4, 1982. e-Pub 1982. PMID: 7180829.
357. Buzdar AU, Legha SS, Hortobagyi GN, Powell KC, Blumenschein GR, Bodey GP. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol 5(4):383-7, 1982. e-Pub 1982. PMID: 6896794.
358. Buzdar AU, Powell KC, Blumenschein GR. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res 42(8 Suppl):3448s-3450s, 1982. e-Pub 1982. PMID: 7083209.
359. Buzdar AU, Legha SS, Blumenschein GR, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Fraschini G, Bodey GP. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer 49(9):1767-70, 1982. e-Pub 1982. PMID: 7042074.
360. Ross MB, Buzdar AU, Blumenschein GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 49(3):413-7, 1982. e-Pub 1982. PMID: 6174195.
361. Ross MB, Buzdar AU, Hortobagyi GN, Lukeman JM. Spontaneous regression of breast carcinoma: follow-up report and literature review. J Surg Oncol 19(1):22-4, 1982. e-Pub 1982. PMID: 7057640.
362. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2(2):163-9, 1982. e-Pub 1982. PMID: 6897369.
363. Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95(6):694-7, 1981. e-Pub 1981. PMID: 7305147.
364. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep 65(9-10):775-9, 1981. e-Pub 1981. PMID: 7273012.
365. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU, Blumenschein GR. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer 48(2):227-32, 1981. e-Pub 1981. PMID: 7237395.
366. Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47(12):2798-802, 1981. e-Pub 1981. PMID: 7260870.
367. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 47(12):2803-6, 1981. e-Pub 1981. PMID: 7260871.
368. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer 47(11):2537-42, 1981. e-Pub 1981. PMID: 6790155.
369. Hortobagyi GN, Smith TL, Swenerton KD, Legha SS, Buzdar AU, Blumenschein GR, Gutterman JU, Hersh EM. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer 47(6):1369-76, 1981. e-Pub 1981. PMID: 7226061.
370. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY, Schell FC, Barnes BC, Burgess MA. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol 18(2):163-72, 1981. e-Pub 1981. PMID: 7300363.
371. Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R. Estrogen receptor: a prognostic factor in breast cancer. Cancer 47:554-60, 1981. e-Pub 1981. PMID: 7226005.
372. Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer 45:742-9, 1980. e-Pub 1980. PMID: 6986970.
373. Krutchik AN, Buzdar AU, Akhtar M, Blumenschein GR. Immune-complex glomerulonephritis secondary to nonspecific immunotherapy. Cancer 45:495-7, 1980. e-Pub 1980. PMID: 6444365.
374. Hagemeister FB, Jr, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer 46:162-7, 1980. e-Pub 1980. PMID: 7388758.
375. Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR. Pulmonary toxicity of mitomycin. Cancer 45:236-44, 1980. e-Pub 1980. PMID: 7351010.
376. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399-406, 1980. e-Pub 1980. PMID: 6159812.
377. Gehan EA, Smith TL, Buzdar AU, Keating MJ, Freireich EJ. Knowledge acquisition from historical data: application to breast cancer patients. Bull Cancer 67(4):437-45, 1980. e-Pub 1980. PMID: 7013864.
378. Hug V, Hortobagyi GN, Buzdar AU, Blumenschein GR, Grose W, Burgess MA, Bodey GP. A phase II study of peptichemio in advanced breast cancer. Cancer 45:2524-8, 1980. e-Pub 1980. PMID: 7378988.
379. Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46:438-45, 1980. e-Pub 1980. PMID: 7397619.
380. Gehan EA, Smith TL, Buzdar AU. Use of prognostic factors in analysis of historical control studies. Cancer Treat Rep 64:373-9, 1980. e-Pub 1980. PMID: 7407774.
381. Hortobagyi GN, Yap HY, Wiseman CL, Blumenschein GR, Buzdar AU, Legha SS, Gutterman JU, Hersh EM, Bodey GP. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep 64(1):157-9, 1980. e-Pub 1980. PMID: 6991103.
382. Ali MK, Soto A, Maroongroge D, Bekheit-Saad S, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Wiseman CL, Shullenberger CC. Electrocardiographic changes after adriamycin chemotherapy. Cancer 43:465-71, 1979. e-Pub 1979. PMID: 421174.
383. Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 63(1):115-20, 1979. e-Pub 1979. PMID: 369682.
384. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol 11(4):325-32, 1979. e-Pub 1979. PMID: 109703.
385. Yap HY, Benjamin RS, Blumenschein GR, Hortobagyi GN, Tashima CK, Buzdar AU, Bodey GP. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep 63(1):77-83, 1979. e-Pub 1979. PMID: 369695.
386. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN, Bodey GP. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 63:1961-4, 1979. e-Pub 1979. PMID: 526929.
387. Legha SS, Benjamin RS, Buzdar AU, Hortobagyi GN, Blumenschein GR. Rubidazone in metastatic breast cancer. Cancer Treat Rep 63(1):135-6, 1979. e-Pub 1979. PMID: 369685.
388. Hortobagyi GN, DiStefano A, Legha SS, Buzdar AU, Blumenschein GR. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep 63:539-41, 1979. e-Pub 1979. PMID: 221118.
389. Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer 44:398-405, 1979. e-Pub 1979. PMID: 383255.
390. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 43:1225-33, 1979. e-Pub 1979. PMID: 445325.
391. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 91:847-52, 1979. e-Pub 1979. PMID: 517883.
392. Hortobagyi GN, Gutterman JU, Blumenschein GR, Yap HY, Buzdar AU, Tashima CK, Burgess MA, Hersh EM. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer 43:1112-22, 1979. e-Pub 1979. PMID: 427716.
393. Krutchik AN, Buzdar AU. Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy. South Med J 72:1615-6, 1979. e-Pub 1979. PMID: 515781.
394. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. Jama 242:49-52, 1979. e-Pub 1979. PMID: 448865.
395. Yap HY, Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Krutchik AN, Benjamin RS, Gutterman JU, Bodey GP, Sr. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol 12:333-41, 1979. e-Pub 1979. PMID: 392197.
396. Legha SS, Buzdar AU, Hortobagyi GN, DiStefano A, Wiseman CL, Yap HY, Blumenschein GR, Bodey GP. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep 63:2053-6, 1979. e-Pub 1979. PMID: 118805.
397. Yap HY, Blumenschein GR, Tashima CK, Hortobagyi GN, Buzdar AU, Wiseman CL. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer 44:32-4, 1979. e-Pub 1979. PMID: 222433.
398. Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol 12:27-40, 1979. e-Pub 1979. PMID: 480951.
399. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, Campos LT, Wheeler WL, Hersh EM, Freireich EJ, Gehan EA. Postoperative adjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. Jama 242:1509-13, 1979. e-Pub 1979. PMID: 470088.
400. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 41:1064-75, 1978. e-Pub 1978. PMID: 638948.
401. Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM. Spontaneous regression of breast carcinoma. Arch Intern Med 138:1734-5, 1978. e-Pub 1978. PMID: 718333.
402. Buzdar AU, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN, Luna MA, Blumenschein GR. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 62:1005-8, 1978. e-Pub 1978. PMID: 688243.
403. Krutchik AN, Buzdar AU, Blumenschein GR, Sinkovics JG. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep 62:1565-7, 1978. e-Pub 1978. PMID: 709557.
404. Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer 41:392-5, 1978. e-Pub 1978. PMID: 630529.
405. Krutchik AN, Blumenschein GR, Tashima CK, Buzdar AU. Cerebromedullospinal disconnection after intraventricular methotrexate. South Med J 71:476-7, 1978. e-Pub 1978. PMID: 635633.
406. Krutchik AN, Buzdar AU, Tashima CK. Cyclophosphamide-induced urticaria. Occurrence in a patient with no cross-sensitivity to chlorambucil. Arch Intern Med 138:1725-6, 1978. e-Pub 1978. PMID: 718329.
407. Hortobagyi GN, Yap HY, Blumenschein GR, Gutterman JU, Buzdar AU, Tashima CK, Hersh EM. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guerin. Cancer Treat Rep 62:1685-92, 1978. e-Pub 1978. PMID: 728894.
408. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Endobronchial metastases in breast carcinoma. West J Med 129:177-80, 1978. e-Pub 1978. PMID: 706354.
409. Yap HY, Salem P, Hortobagyi GN, Bodey GP, Sr, Buzdar AU, Tashima CK, Blumenschein GR. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 62:405-8, 1978. e-Pub 1978. PMID: 348308.
410. Waterfield WC, Tashima CK, Hortobagyi GN, Blumenschein GR, Buzdar AU, Burgess MA. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer 41:1235-9, 1978. e-Pub 1978. PMID: 638989.
411. Samaan NA, deAsis DN, Jr, Buzdar AU, Blumenschein GR. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 41:2084-7, 1978. e-Pub 1978. PMID: 418867.
412. Ali M, Bekheit-Saad S, Soto A, Maroongroge D, Buzdar A, Blumenschein G, Hortobagyi G, Tashima C, Shullenberger C. The significance of QRS voltage changes in patients receiving chemotherapy with doxorubicin hydrochloride (adriamycin). Chest 72:3, 1977. e-Pub 1977.

Invited Articles

1. Kelly CM, Buzdar AU. Anastrozole. Expert Opin Drug Saf 9(6):995-1003, 2010. e-Pub 2010. PMID: 20923259.
2. Kelly CM, Buzdar AU. Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial. Expert Opin Pharmacother 11(3):489-92, 2010. e-Pub 2010. PMID: 20053139.
3. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 10(12):1179-87, 2009. e-Pub 2009. PMID: 19959074.
4. Buzdar AU. Medical oncology: Endocrine-therapy-related symptoms and breast cancer. Nat Rev Clin Oncol 6(6):309-10, 2009. e-Pub 2009. PMID: 19483735.
5. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. e-Pub 2009. PMID: 19150946.
6. Buzdar AU. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc) 44(9):679-92, 2008. e-Pub 2008. PMID: 19137123.
7. Buzdar AU. Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer Suppl 2:S71-8, 2008. e-Pub 2008.
8. Boughey JC, Buzdar AU, Hunt KK. In brief. Curr Probl Surg 45(1):6-11, 2008. e-Pub 2008. PMID: 18206435.
9. Arimidex, Tamoxifen, Trialists' Group AOIC, Forbes JF, Cuzick J, Buzdar AU, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9(1):45-53, 2008. e-Pub 2008.
10. Buzdar AU. Preoperative chemotherapy treatment of breast cancer-A review. Cancer 110(11):2394-407, 2007. e-Pub 2007. PMID: 17941030.
11. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436-44, 2007. e-Pub 2007.
12. Jones KL, Buzdar AU. Trastuzumab in the treatment of early stage breast cancer. Breast Diseases: A Year Book Quarterly 17(1):19-22, 2006. e-Pub 2006.
13. Buzdar AU. Update on the management of inflammatory breast cancer. Clin Adv Hematol Oncol 4(5):344-5, 2006. e-Pub 2006. PMID: 16728943.
14. Buzdar AU. Hormonal therapy in early and advanced breast cancer. Breast J 10(Suppl 1):S19-21, 2004. e-Pub 2004. PMID: 14984485.
15. Buzdar AU. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs of Today (Barc) 40(9):751-64, 2004. e-Pub 2004. PMID: 15538548.
16. Buzdar AU. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. Clinical Breast Cancer 5(Suppl 1):S6-S12, 2004. e-Pub 2004. PMID: 15347433.
17. Buzdar AU. Current developments in hormonal therapy of breast cancer. Clinical Breast Cancer 5(Suppl 1):S4-5, 2004. e-Pub 2004. PMID: 15347432.
18. Buzdar AU. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clinical Cancer Research 10(Suppl 1):355S-61S, 2004. e-Pub 2004. PMID: 14734491.
19. Buzdar AU. The current state of preoperative (neoadjuvant) hormonal therapy for breast cancer. Breast Diseases: A Year Book Quarterly 15(3):219-222, 2004. e-Pub 2004.
20. Buzdar AU. Preceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement. Clinical Cancer Research 10:327s-330s, 2004. e-Pub 2004.
21. Buzdar AU, Hortobagyi GN. Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. Cancer Treat Rev 29(5):449-52, 2003. e-Pub 2003. PMID: 12972364.
22. Buzdar AU. Aromatase inhibitors in breast cancer therapy. Clinical Breast Cancer 4(Suppl 2):S84-8, 2003. e-Pub 2003. PMID: 14667279.
23. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clinical Cancer Research 9:468S-72S, 2003. e-Pub 2003. PMID: 12538502.
24. Buzdar AU. Advanced in endocrine therapy for early and advanced breast cancer. Journal of the Hong Kong College of Radiologists 6(3):165-172, 2003. e-Pub 2003.
25. Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clinical Breast Cancer 4(Suppl 1):S42-8, 2003. e-Pub 2003. PMID: 12756078.
26. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 8:141-8, 2003. e-Pub 2003. PMID: 12697939.
27. Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clinical Cancer Research 9:443S-6S, 2003. e-Pub 2003. PMID: 12538498.
28. Buzdar AU. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther 2(6):623-9, 2002. e-Pub 2002. PMID: 12503208.
29. Assikis VJ, Buzdar A. Aromatase inhibitors: Indications for breast cancer therapy. Am J Cancer 1(2):93-100, 2002. e-Pub 2002.
30. Buzdar AU. Recent advances in adjuvant therapy of breast cancer. Breast Cancer: Management and Treatment 1(1):1-8, 2002. e-Pub 2002.
31. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer 3(Suppl 2):S63-8, 2002. e-Pub 2002. PMID: 12435294.
32. Buzdar AU. New generation aromatase inhibitors--from the advanced to the adjuvant setting. Breast Cancer Research and Treatment 75(Suppl 1):S13-7; discussion S33-5, 2002. e-Pub 2002. PMID: 12353818.
33. Assikis VJ, Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Seminars in Oncology 29(3, Suppl. 11):120-8, 2002. e-Pub 2002. PMID: 12138406.
34. Buzdar AU. Aromatase inhibitors in breast cancer. Breast Cancer Online 4, 2001. e-Pub 2001.
35. Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant?. Clin Cancer Res 7(12):4360s-4368s; discussion 4411s-4412s, 2001. e-Pub 2001. PMID: 11916226.
36. Michaud LB, Jones KL, Buzdar AU. Combination endocrine therapy in the management of breast cancer. Oncologist 6:538-46, 2001. e-Pub 2001. PMID: 11743215.
37. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 28(3):291-304, 2001. e-Pub 2001. PMID: 11402439.
38. Buzdar AU. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?. British Journal of Cancer 85(Suppl 2):6-10, 2001. e-Pub 2001. PMID: 11900212.
39. Buzdar AU. A summary of second-line randomized studies of aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 79:109-14, 2001. e-Pub 2001. PMID: 11850214.
40. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. The Oncologist 6:133-146, 2001. e-Pub 2001.
41. Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res 7(12):4335s-4337s; discussion 4411s-4412s, 2001. e-Pub 2001. PMID: 11916221.
42. Buzdar AU. Article Reviewed: Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology 15(8):978-979, 2001. e-Pub 2001.
43. Buzdar AU, Huml M. Drug: Anastrozole. Outline of Oncology Therapeutics:92, 2000. e-Pub 2000.
44. Buzdar AU. Article Reviewed: Endocrine Therapy for Breast Cancer. Oncology 14(4):493, 2000. e-Pub 2000.
45. Michaud LB, Buzdar AU. Complete Estrogen Blockade for the Treatment of Metastatic and Early Stage Breast Cancer. Drugs & Aging 16(4):261-271, 2000. e-Pub 2000.
46. Michaud LB, Buzdar AU. Endocrine Therapy of Metastatic Breast Cancer. Seminars in Breast Disease: Hormonal Aspects of Breast Cancer 3(2):100-111, 2000. e-Pub 2000.
47. Buzdar A. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. Eur J Cancer 36(Suppl 4):S82-4, 2000. e-Pub 2000. PMID: 11056331.
48. Buzdar A. Exemestane in advanced breast cancer. Anticancer Drugs 11:609-16, 2000. e-Pub 2000. PMID: 11081451.
49. Bland KI, Buzdar AU. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer. Ann Surg Oncol 6 (Suppl. 8):12S-13S, 1999. e-Pub 1999. PMID: 10619454.
50. Buzdar AU Hortobagyi GN. Recent advances in adjuvant therapy of breast cancer. Semin Oncol 26:21-7, 1999. e-Pub 1999. PMID: 10482191.
51. Michaud LB Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 21:297-309, 1999. e-Pub 1999. PMID: 10514021.
52. Buzdar AU. Recent Advances in Endocrine Therapy. Breast Cancer: Perspectives on Data and Developments:35-38, 1999. e-Pub 1999.
53. Buzdar AU. Sequence of hormonal treatments in breast cancer. Sem Br Disease 2:167-679, 1999. e-Pub 1999.
54. Buzdar AU. Tamoxifen for the prevention of breast cancer: An overview of randomized trials. J Clin Outcomes Mgmt 6:S18-S24, 1999. e-Pub 1999.
55. Hortobagyi GN, Hung MC, Buzdar AU. Recent developments in breast cancer therapy. Semin Oncol 26:11-20, 1999. e-Pub 1999. PMID: 10482190.
56. Buzdar AU, Hortobagyi GN. Prospective evaluation of taxol vs. combination chemotherapy with fluorouracil, doxorubicin, cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer. Cancer Inv, Abstracts:57-58, 1999. e-Pub 1999.
57. Pusztai L, Hortobagyi GN, M-C H, Buzdar AU. Advances and Future Directions in Breast Cancer Therapy. Proc 22nd Congress of the International Association for Breast Cancer Research. Athens, Greece, Ioannidou-Mouzaka L, Agnantis NJ, Lopez DM (eds.) Monduzzi Editore, International Proceedings Division, Bologna, Italy:79-83, 1998. e-Pub 1998.
58. Michaud LB, Buzdar AU. Therapeutic interventions in breast cancer: An update. Medscape Oncol 1(4), 1998. e-Pub 1998.
59. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. British J Cancer 78 Suppl 4:16-20, 1998. e-Pub 1998. PMID: 9741784.
60. Rahman ZU, Buzdar AU, Singletary E, Hortobagyi GN. Selection of systemic therapy: Is axillary lymph node status important?. Sem Br Disease 1:157-166, 1998. e-Pub 1998.
61. Buzdar AU, Hortobagyi GN, Singletary SE, Holmes FA, Theriault RL, Walters R, Dhingra K, Booser D, Morris A, Asmar L, Wright-Browne V, Diamandidou E, Witjaksono MA, Strom E, McNeese M, Ames F. : Impact of FAC-Adjuvant Therapy on Mortality of Early Breast Cancer: Long Term Results of the M.D. Anderson Cancer Center Studies. Adjuvant Therapy of Cancer VIII, Sydney E. Salmon (Ed.), Lippincott-Raven Publishers:93-100, 1997. e-Pub 1997.
62. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24(5):S17-65-S17-68, 1997. e-Pub 1997. PMID: 9374097.
63. Michaud LB, Buzdar AU. Commentary, Case 1. Cancer Case Presentations: The Tumor Board 1:4-6, 1997. e-Pub 1997.
64. Buzdar AU, Jonat W, Howell A, Plourde PV. ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. J Steroid Biochem Mol Biol 61:145-9, 1997. e-Pub 1997. PMID: 9365184.
65. Buzdar AU, Hortobagyi GN. Should community oncologists give high-dose chemotherapy requiring G-CSF?. Oncol Rounds 6(3):48, 1997. e-Pub 1997.
66. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol 24(4):S11-13-S11-19, 1997. e-Pub 1997. PMID: 9314293.
67. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol 24(1) (Suppl. 3):S30-3, 1997. e-Pub 1997. PMID: 9071338.
68. Buzdar AU, Hortobagyi GN, Asmar L, Theriault RL, Rahman Z, McNeese M, Singletary S, Ames F. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol 24(5):S17-31-S17-34, 1997. e-Pub 1997. PMID: 9374089.
69. Valero V, Buzdar AU, Hortobagyi GN. Inflammatory Breast Cancer: Clinical Features and the Role of Multimodality Therapy. The Breast Journal 2(5):345-352, 1996. e-Pub 1996.
70. Buzdar AU, Plourde PV, Hortobagyi GN. Aromatase inhibitors in metastatic breast cancer. Semin Oncol 23(4):28-32, 1996. e-Pub 1996. PMID: 8824462.
71. Browne V, Buzdar AU, Hortobagyi GN. Current Status of Adjuvant Therapy of Breast Cancer. (Editorial) The Cancer Journal 9(4):174-176, 1996. e-Pub 1996.
72. Buzdar AU, Hortobagyi GN, Frye D, Valero V. Second-line chemotherapy for metastatic breast cancer including quality of life issues. The Breast 5:312-317, 1996. e-Pub 1996.
73. Valero VV, Buzdar AU, Hortobagyi GN. Locally Advanced Breast Cancer. Oncologist 1:8-17, 1996. e-Pub 1996. PMID: 10387963.
74. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 4(4):715-34, 1995. e-Pub 1995. PMID: 8535907.
75. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 45:199-226, 1995. e-Pub 1995. PMID: 7600278.
76. Hortobagyi GN, Buzdar AU, Strom EA, Ames FC, Singletary SE. Primary chemotherapy for early and advanced breast cancer. Cancer Lett 90:103-9, 1995. e-Pub 1995. PMID: 7720036.
77. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 22:101-4, 1995. e-Pub 1995. PMID: 7541151.
78. Buzdar AU, Hortobagyi GN, Holmes FA, McNeese M, Theriault RL, Singletary SE. M.D. Anderson Cancer Center Adjuvant Therapy Trials in Stage II or III Breast Cancer. Autologous Marrow and Blood Transplantation. Proc of the Seventh International Symposium, KA Dicke, A Keating (Eds.):169-174, 1995. e-Pub 1995.
79. Ibrahim NK, Buzdar AU, Hortobagyi GN. Breast Cancer in the elderly. The Cancer Bulletin 47:212-217, 1995. e-Pub 1995.
80. Buzdar AU. Breast Cancer. Diagnostic Strategies Therapeutic Tactics. Consultant 34(4):606-612, 1994. e-Pub 1994.
81. Ibrahim NK, Forman AD, Podoloff DA, Buzdar AU. Brachial plexopathy and porencephaly in a patient with breast cancer. Case Report, Cancer Bull 46:185-188, 1994. e-Pub 1994.
82. Valero V, Theriault R, Esparza L, Fraschini G, Holmes F, Walters R, Buzdar AU, Raber M, Pazdur R, Bellet R, Bayssas M, Gn H. Phase II Study of Taxotere in Patients with Anthracycline-Resistant Metastatic Breast Cancer. Recent Advances in Chemotherapy: Proc 18th International Congress of Chemotherapy. American Society for Microbiology. Einhorn J, Nord CE, Norrby SR (Eds.):844-845, 1994. e-Pub 1994.
83. Valero V, Buzdar A, Hortobagyi G. Factores Pronosticos enel Cancer de Mama. Proc Seminario Internacional Ultrasonido de la Mama y Mastografia. Mexico City , J Jellins, M Rickard, H Madjar, (eds.), International Breast Ultrasound School, Baden, Switzerland:106-110, 1993. e-Pub 1993.
84. Valero V, Buzdar A, Hortobagyi G. Quimioterapia y hormonoterapia en el cancer de mama metastasico. Proc Seminario Internacional Ultrasonido de la Mama y Mastografia. Mexico City, J Jellins, M Rickard, H Madjar, [eds.], International Breast Ultrasound School, Baden, Switzerland:119-123, 1993. e-Pub 1993.
85. Buzdar AU, Winchester DP, Balch CM. Evaluation of patients after primary therapy for early breast cancer. The Cancer Bull 45(6):528-531, 1993. e-Pub 1993.
86. Buzdar AU, Hortobagyi GN. Recent developments and new directions in adjuvant therapy for breast cancer. The Cancer Bull 45(6):523-527, 1993. e-Pub 1993.
87. Hortobagyi GN, Buzdar AU. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs 45(Suppl 2):10-9; discussion 18-9, 1993. e-Pub 1993. PMID: 7693417.
88. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr 16:161-9, 1993. e-Pub 1993. PMID: 7912522.
89. Buzdar AU. Adjuvant therapy for breast cancer. Advances in Oncology 8(5):10-14, 1992. e-Pub 1992.
90. Buzdar AU. Adjuvant therapy and update of prognostic factors in breast cancer. Breast and Endocrine Second Annual Cancer Update, 1991. e-Pub 1991.
91. Buzdar AU, Hortobagyi GN, McNeese N, Frye D, Holmes F, Fraschini G, Theriault R, Singletary E. Combined modality approach in treatment of inflammatory carcinoma of the breast - M. D. Anderson Cancer Center experience. Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, (eds.) P Banzet, JF Holland, D Khayat, M Weil, (Publ) Springer-Verlag France, Paris:146-148, 1991. e-Pub 1991.
92. Hortobagyi GN, Singletary SE, Buzdar AU, McNeese MD, Ross MI, Holmes FA, Strom E, Theriault RL, Sneige N. Primary chemotherapy for breast cancer - M. D. Anderson experience. Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, (eds.) P Banzet, JF Holland, D Khayat, M Weil, (Publ) Springer-Verlag France, Paris:146-148, 1991. e-Pub 1991.
93. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol 13(Suppl 1):S54-6, 1990. e-Pub 1990. PMID: 2291460.
94. Hortobagyi GN, Dunphy F, Buzdar AU, Spitzer G. Dose intensity studies in breast cancer--autologous bone marrow transplantation. Prog Clin Biol Res 354B:195-209, 1990. e-Pub 1990. PMID: 2236166.
95. Buzdar AU. Combined chemohormonal therapy for metastatic breast cancer. Cancer Chemotherapy: Challenges for the Future 5:257-264, 1990. e-Pub 1990.
96. Buzdar A, Hortobagyi G, Kau S, Patel H, Hug V, Holmes F, Fraschini G, Singletary S, Ames F. Evaluation of risk and benefits of doxorubicin-containing (FAC) adjuvant chemotherapy in breast cancer - M. D. Anderson Cancer Center experience. Proceedings of the 16th International Congress of Chemotherapy, June 1989, Israel:781.1-781.2, 1990. e-Pub 1990.
97. Buzdar AU, Hortobagyi GN. Treatment of early and advanced breast cancer. Syllabus American College of Physicians 1989-1990 Postgraduate Courses Course (#906), 1989. e-Pub 1989.
98. Buzdar AU. Recent Advances in the treatment of early and advanced breast cancer. Oncol. (Life Sci. Adv.) 8:43-58, 1989. e-Pub 1989.
99. Buzdar AU. Chemotherapeutic approaches to advanced breast cancer. Semin Oncol 15(3):65-70, 1988. e-Pub 1988. PMID: 3293220.
100. Buzdar A, Hortobagyi G, Frye D, Ames F, Singletary S, McNeese M, Montague E. Inflammatory carcinoma of the breast: Preliminary results of combined modality approach. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, Turkey:438-439, 1987. e-Pub 1987.
101. Buzdar AU. Future directions of adjuvant and preventive therapy of breast cancer. Reviews on Endocrine-related Cancer 27:11-15, 1987. e-Pub 1987.
102. Buzdar AU. Endocrine-dependent breast cancer-critical assessment of recent advances. The Cancer Bulletin 39(5):272, 1987. e-Pub 1987.
103. Feinberg BA, Ewer MS, Batizy S, Buzdar AU. Clostridium perfringens infection of the pericardium: A rare form of septic pericarditis. Cancer Bull 39(2):116-117, 1987. e-Pub 1987.
104. Spitzer G, Buzdar A, Hortobagyi G, Horwitz L, Jagannath S, Smith K, Dicke K. High-dose chemotherapy intensification and autologous bone marrow transplantation with emphasis on breast carcinoma. Proceedings of the Third International Symposium, Autologous Bone Marrow Transplantation III:455-463, 1986. e-Pub 1986.
105. Hortobagyi GN, Buzdar AU. Progress in inflammatory breast cancer: Cause for cautious optimism. J Clin Oncol 4(12):1727-1729, 1986. e-Pub 1986.
106. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1:105-9, 1986. e-Pub 1986. PMID: 3534581.
107. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand 58 ( Pt A):357-63, 1986. e-Pub 1986. PMID: 3596041.
108. Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr 1:81-5, 1986. e-Pub 1986. PMID: 3534594.
109. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi GN. Pre-and post-operative combination chemotherapy in breast cancer - M. D. Anderson experience. Proc of International Symposium of Senology, Evaluation of the risk of breast cancer primary chemotherapy, Liege-Belgium:287-295, 1985. e-Pub 1985.
110. Buzdar AU. Natural history of stage IV breast cancer. Autologous bone marrow transplantation. Proc of the 1st International Symposium. (eds.) K.A. Dicke, G. Spitzer and R. Zander:185-188, 1985. e-Pub 1985.
111. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol 11(3):28-31, 1984. e-Pub 1984. PMID: 6385262.
112. Buzdar AU. Adjuvant therapy of breast cancer. Tex Med 80:37-8, 1984. e-Pub 1984. PMID: 6484865.
113. Blumenschein GR, Yap HY, Issell BF, Hortobagyi GN, Buzdar AU. The role of VP-16 (Etoposide) in the treatment of metastatic breast cancer. Etoposide (VP-16-213) Current Status & New Developments (eds.) Brain F. Issell, Franco M. Muggia, and Stephen K. Carter; Academic Press:253-260, 1984. e-Pub 1984.
114. Buzdar AU, Blumenschein GR. Summaries of the papers presented at the 13th International Congress of Chemotherapy (SE 12.1.10 and SE 12.0.10/A) on breast cancer. Cancer Treat Rev 11:315-319, 1984. e-Pub 1984.
115. Buzdar AU. Endocrine therapies for breast cancer. The management of breast cancer through endocrine therapies. Excerpta Medica. (ed.) Joseph C. Allegra:29-37, 1984. e-Pub 1984.
116. Buzdar AU, Blumenschein GR. Breast cancer. Cancer Treat Rev 11:315-9, 1984. e-Pub 1984. PMID: 6534512.
117. Holmes FA, Buzdar AU. Isolated lesions in a patient with a history of recurrent breast cancer - A management dilemma. The Cancer Bull 36(6):292-294, 1984. e-Pub 1984.
118. Hortobagyi GN, Jr FH, Mughal AW, Buzdar AU, Yap HY, Blumenschein GR. Role of carcinoembryonic antigen for followup of breast cancer patients. Current Controversy in Breast Cancer:461-465, 1984. e-Pub 1984.
119. Hortobagyi GN, Smith TL, Blumenschein GR, Legha SS, Yap HY, Buzdar AU. Clinical prognostic factors of response. Current Controversy in Breast Cancer:255-259, 1984. e-Pub 1984.
120. Bodey GP, Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU. A randomized comparative study of vinblastine, vindesine, and vincristine in patients with refractory metastatic breast cancer. Drug Exp Clin 8:559-564, 1982. e-Pub 1982.
121. Buzdar AU, Blumenschein GR, Hortobagyi GN, Legha SS, Yap HY, Campos LT, Hersh EM. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin (adriamycin) and cyclophosphamide, with or without BCG immunotherapy in stage II or III breast cancer. Immunotherapy of Human Cancer. Elsevier North Holland, Inc., Terry/Rosenberg, eds:175-181, 1982. e-Pub 1982.
122. Fraschini G, DiStefano A, Yap HY, Barnes B, Buzdar AU, Hortobagyi G, Blumenschein GR. Chemotherapy with dibromodulcitol (DBD), adriamycin (ADR), cyclophosphamide (DYT) for metastatic breast carcinoma. Proc XII International Congress of Chemotherapy, FLorence, Italy:1485-1487, 1981. e-Pub 1981.
123. Legha SS, Swenerton KD, Buzdar AU, Hortobagyi GN, Smith TL, Bodey GP, Blumenschein GR. Patterns of relapse after complete remission in metastatic breast cancer treatment with chemoimmunotherapy. The Cancer Bull 31:108, 1979. e-Pub 1979.
124. Ali MK, Bekheit-Saad S, Ewer MS, Soto A, Buzdar AU, Blumenschein GR, Tashima CK, Wiseman CL, Hortobagyi GN, Maroongroge DP. Noninvasive evaluation of myocardial function in patients receiving adriamycin chemotherapy. Cancer Bulletin 31:93-94, 1979. e-Pub 1979.
125. Buzdar AU, Blumenschein GR, Krutchik AN, Tashima CK, Hortobagyi GN, Gutterman JU, Hersh EM. Combined modality approach for inflammatory breast cancer: Prolongation of disease-free interval and survival. The Cancer Bull 31:95-96, 1979. e-Pub 1979.

Review Articles

1. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26(5):814-9, 2008. e-Pub 2008. PMID: 18258991.
2. Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 40:1572-83, 2006. e-Pub 2006. PMID: 16912252.
3. Buzdar AU. Anastrozole for breast cancer: recent advances and ongoing challenges. Expert Rev Anticancer Ther 6:839-48, 2006. e-Pub 2006. PMID: 16761927.
4. Buzdar AU. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis 24:107-17, 2006. e-Pub 2006. PMID: 16917143.
5. Buzdar AU. TAS-108: a novel steroidal antiestrogen. Clin Cancer Res 11(2 Pt 2):906s-8s, 2005. e-Pub 2005. PMID: 15701885.
6. Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer 101(7):1482-9, 2004. e-Pub 2004. PMID: 15378476.
7. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 11(3):391-406, 2004. e-Pub 2004. PMID: 15369444.
8. Buzdar AU. Breast cancer in men. Oncology (Williston Park) 17(10):1361-4; discussion 1364, 1369-72, 2003. e-Pub 2003. PMID: 14606362.
9. Buzdar AU. Role of anastrozole in adjuvant therapy for postmenopausal patients. Semin Oncol 30(5 Suppl 16):21-9, 2003. e-Pub 2003. PMID: 14613023.
10. Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP. A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J 9(3):213-22, 2003. e-Pub 2003. PMID: 12752630.
11. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8(4):335-41, 2003. e-Pub 2003. PMID: 12897330.
12. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95(9):2006-16, 2002. e-Pub 2002. PMID: 12404296.
13. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 137(8):678-87, 2002. e-Pub 2002. PMID: 12379069.
14. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 7(9):2620-35, 2001. e-Pub 2001. PMID: 11555572.
15. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 77(2):139-47, 2001. e-Pub 2001. PMID: 11398169.
16. Buzdar AU. Tamoxifen's clinical applications: old and new. Arch Fam Med 9(9):906-12, 2000. e-Pub 2000. PMID: 11031399.
17. Buzdar AU. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer 6(2):219-25, 1999. e-Pub 1999. PMID: 10731112.
18. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 4(3):527-34, 1998. e-Pub 1998. PMID: 9533518.
19. Hortobagyi GN, Buzdar AU. Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. Cancer Invest 16(6):385-90, 1998. e-Pub 1998. PMID: 9679529.
20. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16(1):348-53, 1998. e-Pub 1998. PMID: 9440763.
21. Roseman BJ, Buzdar AU, Singletary SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol 66(3):215-20, 1997. e-Pub 1997. PMID: 9369969.
22. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol 18(5):407-17, 1995. e-Pub 1995. PMID: 7572758.
23. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13(2):513-29, 1995. e-Pub 1995. PMID: 7844613.
24. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg 18(1):87-92, 1994. e-Pub 1994. PMID: 8197782.
25. Cohen PR, Buzdar AU. Metastatic breast carcinoma mimicking an acute paronychia of the great toe: case report and review of subungual metastases. Am J Clin Oncol 16(1):86-91, 1993. e-Pub 1993. PMID: 8424412.
26. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 117(9):771-7, 1992. e-Pub 1992. PMID: 1416579.
27. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 10(6):1014-24, 1992. e-Pub 1992. PMID: 1588366.
28. Ziegler LD, Buzdar AU. Recent advances in the treatment of breast cancer. Am J Med Sci 301(5):337-52, 1991. e-Pub 1991. PMID: 2021157.
29. Ziegler LD, Buzdar AU. Current status of adjuvant therapy of early breast cancer. Am J Clin Oncol 14(2):101-10, 1991. e-Pub 1991. PMID: 2028918.
30. Buzdar AU. Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol 6(2):77-82, 1990. e-Pub 1990. PMID: 2180045.
31. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62(12):2507-16, 1988. e-Pub 1988. PMID: 3056604.
32. Smith L, Buzdar AU, Rusch V, Blocker SH, McKenna RJ. Post-mastectomy angiosarcoma: case report and review of the literature. Tex Med 80(7):43-4, 1984. e-Pub 1984. PMID: 6379971.

Professional Educational Materials

1. Come SE, Buzdar AU. Recent advances and future directions in endocrine manipulation of breast cancer. Clinical Cancer Research, 2006.
2. Come SE, Buzdar AU. Recent advances and future directions in endocrine manipulation of breast cancer, 2005.
3. Come SE, Buzdar AU. Recent advances and future directions in endocrine manipulation of breast cancer, 2004.
4. Come SE, Buzdar AU. Recent advances and future directions in endocrine manipulation of breast cancer, 2003.
5. Buzdar AU. Hormonal agents in the treatment of breast cancer: current status, 2002.
6. Buzdar AU. Current Management of Breast Cancer: Metastasis, 2001.
7. Hortobagyi G, Dixon JM, Buzdar A, Ganz P, Petrek JA. Conversations with Oncology Leaders: Bridging the gap between research and patient care, 2001.
8. Buzdar AU, Elledge RM, Osborne CK. An Update on Aromatase Inhibitors as Therapy for Advanced Breast Cancer. Discovery International, 2001.
9. Brodie AH, Buzdar AU, Goss P, Lonning PE, Miller WR. Optimizing Anti-Aromatase Agents in Breast Cancer: An Accredited Program for Physicians, 2000.
10. Buzdar AU. Monograph on Breast Cancer: Endocrine Therapies, 1996.
11. Utian WH, Ades TB, Buzdar AU, Osuch JR, Petrek JA, Pilgrim CA, Wilcox PM. Overcoming your patients’ fear of breast cancer, 1994.
12. Ueno NT, Buzdar AU, Hortobagyi GN. Inflammatory Breast Cancer, 1994.
13. Osborne CK, Bonadonna G, Buzdar AU, Davidson NE, Donegan WL, Margolese RG, Pritchard KI. Controversies in the Treatment of Early Breast Cancer, 1993.
14. Hortobagyi GN, Buzdar AU. 17 Years’ experience with anthracycline-containing regimens at the M.D. Anderson Cancer Center, 1992.
15. Buzdar AU. Pitfalls and Controversies in Diagnosis and Treatment, 1988.
16. Buzdar AU. Status of Adjuvant Therapy in Breast Cancer, 1988.
17. Buzdar AU. Future direction of adjuvant and preventive therapy of breast cancer, 1987.
18. Buzdar AU. The Reviewed Monograph on Trilostane for American Society of Hospital Pharmacists, 1987.
19. Buzdar AU. Endocrine therapy in the management of advanced breast cancer, 1983.
20. Buzdar AU. Adjuvant chemotherapy for stage II and III breast cancer, 1983.
21. Segaloff A, Ansfield FJ, Buzdar AU, Tall RW. A Round Table Discussion for Bristol, 1982.

Other Articles

1. Buzdar AU Oncology-Primary Care of Cancer: Recommendations for Screening, Diagnosis, and Management. (ed.) E.A. Mortimer, Case Western Reserve University School of Medicine (collab.). Annals of Internal Medicine 108(2):317-318, 1988.
2. Buzdar AU Diseases of the Breast. The Cancer Bulletin 39(1):67, 1987.

Editorials

1. Buzdar AU. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 24:2409-11, 2006. PMID: 16682721.
2. Buzdar AU. Dietary modification and risk of breast cancer. JAMA 295(6):691-2, 2006. PMID: 16467239.
3. Buzdar AU. Review of Article: "Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer" by Perez E and Muss HB. Oncology 19(14):1773-4, 2005.
4. Theriault RL, Buzdar AU. Review of Article “Pregnancy and Breast Cancer: Epidemiology, Treatment, and Safety Issues” by Partridge A and Schapira L. Oncology 19(6):698-700, 2005.
5. Buzdar AU. Commentary of article “Letrozole improved disease-free survival in postmenopausal women after tamoxifen treatment for breast cancer” by Goss PE, Ingle JN, Martino S, et al. Evidence-Based Obstetrics and Gynecology 6:91-92, 2004.
6. Buzdar AU. Anastrozole: a viewpoint. Drugs 62(17):2491-2492, 2002.
7. Buzdar AU. Aromatase inhibitors versus tamoxifen: Which is the better choice? . Breast Diseases: a Year Book Quarterly 12(2):148-150, 2001.
8. Buzdar AU, Hortobagyi GN. Review of Article "Update on Adjuvant Chemotherapy for Early Breast Cancer" by McCarthy NJ and Swain SM. Oncology 14(9):1280-1283, 2000.
9. Buzdar AU. Tamoxifen in breast cancer. Breast Diseases: A Year Book Quarterly 10(1):28-29, 1999.
10. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998. (Editorial: Aman U. Buzdar). Breast Diseases: A Year Book Quarterly 9(3):311, 1998.
11. Willsher PC, Robertson JFR, Chan SY, et al. Locally advanced breast cancer: Early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 33:45-49, 1997. (Editorial: Aman U. Buzdar). Breast Diseases: A Year Book Quarterly 8(3):265, 1997.
12. Buzdar AU, Michaud LL. The Goss/Tye Article Reviewed. Oncology 11:1707-1708, 1997.
13. Miller AA, Lipton A, Henderson IC, et al. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer 78:789-793, 1996. (Editorial: Aman U. Buzdar). Breast Diseases: A Year Book Quarterly 8(2):169-170, 1997.
14. Buzdar AU, Brown V, Hortobagyi GN. Current Status of Adjuvant Therapy of Breast Cancer. Cancer J 9(4):174-176, 1996.
15. Coombes RC, Cancer Group FTIC. Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Versus Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy in Premenopausal Women with Axillary Node-positive Operable Bresat Cancer: Results of a Randomized Trial (J Clin Oncol 14:35-45, 1996). (Editorial: Aman U. Buzdar). Breast Diseases: A Year Book Quarterly 7(4):397-399, 1996.
16. Buzdar, Aman U. Cancer in the Elderly: The University of Texas M. D. Anderson Cancer Center. (Editors: Aman U. Buzdar and Michael S. Ewer). The Cancer Bulletin, May-June 47(3), 1995.
17. Schwartz GF, Birchansky CA, Kormarnicky LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM, McFarlane FJ. Induction Chemotherapy followed by breast conservation for locally advanced carcinoma of the breast (Cancer 73:362-369, 1994). (Editorial: Aman U. Buzdar). Breast Diseases: A Year Book 5(4):84-85, 1995.
18. Cold S, et al. The Influence of chemotherapy on survival after recurrence in breast cancer: A population-based study of patients treated in the 1950s, 1960s, and 1970s. (Editorial: Buzdar AU). Breast Diseases: A Year Book 5(2):71-73, 1994.
19. Hortobagyi GN Buzdar AU. Progress in inflammatory breast cancer: cause for cautious optimism. J Clin Oncol 4(12):1727-9, 1986. PMID: 3783199.

Abstracts

1. Buzdar A, Hunt K, Buchholz TA, Taylor SH, Hortobagyio GN, Hess KR. Improving survival of patients with breast cancer over the past 6 decades: The University of Texas M.D. Anderson Cancer Center experience. 2010 Breast Cancer Symposium, 2010. e-Pub 2010.
2. Buzdar AU, McCall L, Suman V, Beitsch PD, Ewer M, Meric-Bernstam F, Leitch AM, Boughey JC, Ellis ME, Unzeitig G, Royce M, Hunt KK. A randomized phase III trial comparing a neoadjuvant regimen of FEC-75 followed by paclitaxel plus trastuzumab with a neoadjuvant regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER-2 positive operable breast cancer, ACOSOG Z1041. 2010 American Society of Clinical Oncology Annual Meeting, 2010. e-Pub 2010.
3. Green MC, Buzdar AU, Valero V, Frye D, Christmas J, Carter C, Cohen D, Hortobagyi GN. Rates of adverse events with low-dose dexamethasone (dex) as premedication of weekly paclitaxel (Pac) utilized as adjuvant/neoadjuvant therapy for operable breast cancer. 2009 American Society of Clinical Oncology Breast Cancer Symposium, 2009. e-Pub 2009.
4. Buzdar AU, Valero V, Ibrahim NK, Theriault RL, Pusztai L, Hunt KK, Esteva FJ, Ewer MS, Hortobagyi GN. Seventy-two month update of randomized trial of preoperative therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy with or without concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer. 2009 American Society of Clinical Oncology Breast Cancer Symposium, 2009. e-Pub 2009.
5. Buzdar AU, Ballman KV, Meric-Bernstam F, Boughey JC, Leitch AM, Unzeitig G, Ellis MJ, Ewer MS, Beitsch PD, Hunt KK. Initial safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2 positive operable breast cancer (ACOSOG Z1041). 2009 American Society of Clinical Oncology Breast Cancer Symposium, 2009. e-Pub 2009.
6. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andre F, Buzdar AU, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in plasma protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using MALDI-TOF/MS procedure. 2009 American Society of Clinical Oncology Breast Cancer Symposium, 2009. e-Pub 2009.
7. Buzdar AU, Green MC, Broglio KR, Valero V, Ibrahim NK, Hunt KK, Hortobagyi GN. Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer. American Society of Clinical Oncology, 2009. e-Pub 2009.
8. Buzdar AU, Cuzick J. Is overall survival an appropriate enpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up. 2008 American Society of Clinical Oncology, Annual Meeting, J Clin Oncol 26(May 20 Suppl), 2008. e-Pub 2008.
9. Esteva FJ, Anderson K, Lin F, Nahta R, Mejia J, Altundag K, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. Pharmacogenomic analysis of HER2 amplified breast cancer treated wiht preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide, (T/FEC) chemotherapy. Proc American Society of Clinical Oncology 24(18S):14s (asbtr 545), 2006. e-Pub 2006.
10. Mazouni C, Hall A, Anderson K, Peintinger F, Fritsche H, Andre F, Yekell S, Arun B, Buzdar AU, Esteva F, Pusztai L, Cristofanilli M. An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to treatment. San Antonio Breast Cancer Symposium 29th Annual Meeting:asbtr 1039, 2006. e-Pub 2006.
11. Trialists' Group BAOBOTA. Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Proc American Society of Clinical Oncology 24(18S):15s (abstr 551), 2006. e-Pub 2006.
12. Cristofanilli M, Valero V, Buzdar AU, Gonzalez-Angulo AM, S-W K, Broglio KR, Islam R, Sneige N, Krishnamurthy S, Ueno NT, Hunt KK, Kuerer HM, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC): patterns of recurrence and micrometastatic homing. San Antonio Breast Cancer Symposium 29th Annual Meeting:abstr 3093, 2006. e-Pub 2006.
13. Johnson PH, Krishnamurthy S, Buzdar A, Hortobagyi G, Moulder S. Nuclear staining of topoisomerase II (topo II) may predict response to anthracycline but not taxane-based neoadjuvant chemotherapy regimens. San Antonio Breast Cancer Symposium 29th Annual Meeting:abstr 1024, 2006. e-Pub 2006.
14. Robidoux A, Buyse M, Buzdar A, Geyer CE, Pajon E, DiNunno L, Desai A, Fehrenbacher L, Kuerer H, Liles D, Paik S, Mamounas E, Wolmark N. Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane®) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation research programs (FRP). San Antonio Breast Cancer Symposium 29th Annual Meeting:abstr 3068, 2006. e-Pub 2006.
15. Arun B, Valero V, Logan C, Rivera E, Brewster A, Green M, Buzdar A, Browne D, Hortobagyi GN, Sneige N. Random periareolar fine needle aspiration compared to ductal lavage for tissue acquisition in short-term breast cancer chemoprevention studies. San Antonio Breast Cancer Symposium 29th Annual Meeting:abstr 1048, 2006. e-Pub 2006.
16. Symmans WF, Hatzis C, Sotiriou C, Anderson SK, Valero V, Booser DJ, Buzdar AU, Hess KR, Hortobagyi GN, Pusztai L. A genomic index of estrogen receptor reporter genes predicts benefit from adjuvant endocrine therapy independent of baseline prognosis. San Antonio Breast Cancer Symposium 29th Annual Meeting:Abstr 1027, 2006. e-Pub 2006.
17. Baum M, Cuzick J, Howell A, Buzdar A, Demicheli R, Greco M, Retsky M, Hrushesky B, Trialists' Group OBOTA, Institute TM. An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database. Proc American Society of Clinical Oncology 23(16S):31s(abstr 612), 2005. e-Pub 2005.
18. Hanrahan EO, Frye D, Buzdar A, Theriault RL, Booser DJ, Valero V, Singletary SE, Gajewski JL, Champlin RE, Hortobagyi GN. Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma. Proc American Society of Clinical Oncology 23(16S):44s(abstr 663), 2005. e-Pub 2005.
19. Overmoyer B, Waintraub S, Kaufman PA, Doyle T, Moore H, Modiano M, Kroener J, Zhang X, Buzdar AU, Demario M. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. Proc American Society of Clinical Oncology 23(16S):72s(abstr 778), 2005. e-Pub 2005.
20. Altundag K, Kim E, Broglio K, Buzdar AU, Hortobagyi G, Arun B. Characterization of bone material density (BMD) at the time of diagnosis in postmenopausal patients with operable breast cancer: Association with clinical-pathological findings. Proc American Society of Clinical Oncology 23(16S):864s(abstr 9611), 2005. e-Pub 2005.
21. Buzdar AU, Valero V, Ibrahim N, Francis D, Theriault RL, Green M, Hunt K, Sahin A, Buchholz T, Hortobagyi GN. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population. Breast Cancer Research and Treatment 94 (Suppl 1):S223 (abstr 5049), 2005. e-Pub 2005.
22. Guarneri V, Broglio KR, Kau S, Cristofanilli M, Buzdar AU, Valero V, Buchholz TA, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in patients with hormone receptor-postive breast cancer. Breast Cancer Research and Treatment 94(Suppl 1):S223 (abstr 5049), 2005. e-Pub 2005.
23. Buzdar AU, Silverman P, Kaufman PA, Waintraub S, Doyle T, Kroener J, Robinson P, Perez, Zhang X, DeMario M. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. Breast Cancer Research and Treatment 94(suppl 1):S69(abstr 1087), 2005. e-Pub 2005.
24. Buzdar AU. Role of trastuzumab (Herceptin) in neoadjuvant therapy of HER-2 positive breast cancer. Pro of the 18th Asia Pacific Cancer Conference 37(4):66(abstr 18-2), 2005. e-Pub 2005.
25. Buzdar AU, Trialists' Group OBOTA. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 months results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Proc American Society of Clinical Oncology 23(16S):30S (abstr 608), 2005. e-Pub 2005.
26. Gonzalez-Angulo AM, Kau SW, Broglio K, Buzdar AU, Theriault RL, Valero V, Sneige N, Frye D, Hortobagyi GN, Cristofanilli M. Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features. Proc American Society of Clinical Oncology 23:42, 2004. e-Pub 2004.
27. Buchholz TA, Woodard WA, Tucker SL, Strom EA, Hunt KK, Buzdar AU, Perkins GH, Schechter NR, Hortobagyi GN. Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy. Proc American Society of Clinical Oncology 23:15, 2004. e-Pub 2004.
28. Eralp Y, Smith TL, S-W K, Valero V, Buzdar A, Hortobagyi GN, Arun B. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. Proc American Society of Clinical Oncology 23:27, 2004. e-Pub 2004.
29. Buzdar AU, Hunt K, Smith T, Francis D, Ewer M, Booser D, Singletary E, Buchholz T, Sahin A, Hortobagyi GN. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc American Society of Clinical Oncology 23:7, 2004. e-Pub 2004.
30. Leonard R, Bundred N, Buzdar A, Canney P, Rea D, Stewart A, Verrill M. Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer. Proc American Society of Clinical Oncology 23:12, 2004. e-Pub 2004.
31. Valero V, Gill E, Paton V, H-Y C, Buzdar AU, Park G, Hortobagyi G, Ewer M. Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. Proc American Society of Clinical Oncology 23:20, 2004. e-Pub 2004.
32. Hortobagyi GN, S-W K, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, Valero V. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? . Proc American Society of Clinical Oncology 23:23, 2004. e-Pub 2004.
33. Ibrahim NK, Macneil S, Headley JA, Bisotooni KT, Buzdar AU, Hortobagyi GN. Effect of paclitaxel (P)-based chemotherapy on the ovarian failure (OF) of breast cancer patients (pts): A retrospective study. Proc Am Soc Clin Oncol 22:753, 2003. e-Pub 2003.
34. Buzdar A. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 47 months. Breast Cancer Research and Treatment 77:295, 2003. e-Pub 2003.
35. Blakely J, Buzdar A, Chang H, et al. A phase I and pharmacokinetic study of TAS-108 in previously treated patients with metastatic breast cancer. Proc. Am. Assoc. Cancer Res 44:1227, 2003. e-Pub 2003.
36. Giordano SH, Cohen DS, Buzdar AU, Perkins GH, Hortobagyi GN. A population-based analysis of male breast cancer. Proc Am Soc Clin Oncol 22:875, 2003. e-Pub 2003.
37. Trigo Perez JM, Gil M, Miles D, Fornier M, Buzdar AU, Barrett-Lee P, Dhingra K, Demario M, Baselga J. A multicenter phase II study of the cell cycle inhibitor Ro 31-7453 in patients with metastatic breast cancer who have failed chemotherapy with an anthracycline and a taxane. . Proc Am Soc Clin Oncol 22:16, 2003. e-Pub 2003.
38. Ruggeri A, Mininberg ED, Valero V, Kau SW, Buzdar AU, Hortobagyi GN. The natural history of metachronous contralateral breast cancer (CBC) in women treated with prior adjuvant or neoadjuvant therapy. Proc Am Soc Clin Oncol 22:29, 2003. e-Pub 2003.
39. Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D, Guerra L, Sahin A, Ames F, Smith T, Singletary E, Hortobagyi GN. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Research and Treatment 82(Suppl 1):S69, 2003. e-Pub 2003.
40. Buchholz TA, Hang E, Berry D, Strom EA, McNeese MD, Pusztai L, Kuerer H, Buzdar AU, Hortobagyi GN, Valero V, Perkins GH, Sahin A. Her2-neu overexpression does not increase the risk of local-regional recurrence for pateitns treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation. Int J Radiat Oncol Biol Phys 57(2 Suppl):S201, 2003. e-Pub 2003.
41. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of local-regional recurrence in patients with locally-advanced breast cancer treated with neoajduvant chemotherapy, mastectomy, and radiation. Breast Cancer Research and Treatment 82(Suppl 1):S182, 2003. e-Pub 2003.
42. Giordano SH, Perkins GH, Garcia SM, Middleton LP, Buzdar AU, Hortobagyi GN. Male breast cancer: The MD Anderson experience with adjuvant therapy. Breast Cancer Research and Treatment 82(Suppl 1):S42, 2003. e-Pub 2003.
43. Huang EH, Tucker S, Srom E, McNeese M, Kuerer H, Hortobagyi G, Buzdar A, Valero V, Perkins G, Hunt K, Sahin A, Buchholz T. Radiation treatment improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys 57(2 Suppl):S238, 2003. e-Pub 2003.
44. Leonard RCF, Bundred N, Buzdar A, Canney P, Rea D, Spittle MF, Stewart AL, Verrill M. Multi-center clinical trials of trilostane (modrenal) for advanced breast cancer in post-menopausal women. Breast Cancer Research and Treatment 82(Suppl 1):S102, 2003. e-Pub 2003.
45. Valero V, Buzdar AU, S-W K, Theriault RL, Booser D, McNeese MD, Singletary SE, Hortobagyi GN. Long-term results of patients with breast cancer with 10 or more positive axillary lymph node treated with adjuvant anthracyline-containing therapy. The University of Texas M.D. Anderson Cancer Center (MDACC) experience. Breast Cancer Research and Treatment 82(Suppl 1):S30, 2003. e-Pub 2003.
46. Garg A, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Schechter N, Sahin AA, Valero V, Tucker SL, Buchholz TA. Clinical stage T3 disease or pathologic involvement of four or more lymph nodes predict for local-regional recurrence in stage II breast cancer treated with neoadjvuant chemotherapy and mastectomy without radiation. Breast Cancer Research and Treatment 82(Suppl 1):S182, 2003. e-Pub 2003.
47. Chagpar AB, Mirza AN, Buzdar AU, Dempsey PJ, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Middlton LP, Ross MI, Sahin AA, Singletary SE. Accuracy of physical examination (PE), ultrasonography (US) and mammography (M) in predicting residual pathological tumor size (RPTS) in patients treated with neoadjvuant chemotherapy (NAC). . Breast Cancer Research and Treatment 82(Suppl 1):S52, 2003. e-Pub 2003.
48. Yu T, Whitman GJ, Thames HD, Strom E, McNeese MD, Perkins GH, Schechter N, Kau S, Buzdar AU, Hortobagyi GN, Thomas E, Buchholz TA. Clinically-relevant pneumonitis is not increased in breast cancer patients treated with sequential paclitaxel and radiation. . Int J Radiat Oncol Biol Phys 57(2 Suppl):S127-8, 2003. e-Pub 2003.
49. Buzdar AU. Anastrozole: An aromatase inhibitor as a potential preventative agent in women at high risk of developing breast cancer. . AACR: Frontiers in Cancer Prevention Research Program and Proceedings Abstract Book, Boston, MA:181, 2002. e-Pub 2002.
50. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales M, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault R, Carter C, Singletary SE, Kuerer HM, Hunt K, Strom E, Hortobagyi N. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randommized trial. . Proc Am Soc Clin Oncol 21:35a, 2002. e-Pub 2002.
51. Li Z, Ibrahim NK, Wang M, Valero V, Theriault RL, Buzdar AU, Hortobagyi GN. Colitis in breast cancer patients (pts) treated with taxane-based chemotherapy (TBC): M.D. Anderson Cancer Center experience. Proc Am Soc Clin Oncol 21:57a, 2002. e-Pub 2002.
52. Giordano SH, Buzdar AU, Kau SWC, Hortobagyi GN. Improvement in breast cancer survival: results from M.D. Anderson Cancer Center protocols from 1975-2000. Proc Am Soc Clin Oncol 21:54a, 2002. e-Pub 2002.
53. Michaud LB, Buzdar AU, Rubin S, Steinberg M, Yin H, Aronson L, Nabholtz JM. The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:55a, 2002. e-Pub 2002.
54. Buzdar AU. Arimidex (anastrozole) - the ideal aromatase inhibitor for the adjuvant setting?. Adjuvant Therapy of Primary Breast Cancer: 7th International Conference. AstraZeneca Satellite Syposium Abstract Book. St. Gallen, Switzerland, 2001. e-Pub 2001.
55. Lozada JA, Abu Shullaih S, Hoy E, Smith TL, Buzdar A. Effects of pregnancy following treatment for breast cancer on survival and risk of recurrence. Proc Am Soc Clin Oncol 20:37a, 2001. e-Pub 2001.
56. Esteva FJ, Theriault R, Rivera E, Chang HY, Cristofanilli M, Buzdar A, Booser D, Pusztai L, Rosales M, Hortobagyi GN. Phase I safety and dose-finding study of human mammary epithelial cell-derived mammastatin (native mammastatin) for metastatic breast cancer. 2001 Annual Meeting of the American Association for Cancer Research, 2001. e-Pub 2001.
57. Thurlimann BJ, Bonneterre J, Buzdar A, Nabholtz J, Robertson JF, Sahmoud T. First line endocrine therapy in postmenopausal patients with advanced breast cancer and visceral metastases: Anastrozole (Arimidex) versus Tamoxifen. Proc Am Soc Clin Oncol 20:22b, 2001. e-Pub 2001.
58. Buzdar AU, O'Shaughnessy J, Hudis C, Booser D, Pippen J, Jones S, Munster P, Enas N, Melemed A, Winer E, Storniolo A. Preliminary results of a randomized double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene (AZ) in patients (Pts) with locally advanced or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20:45a, 2001. e-Pub 2001.
59. Green MC, Buzdar AU, Smith T, Singletary SE, Carter C, Rosales MF, Booser DJ, Pusztai L, Cristofanilli M, Theriault R, Ibrahim NK, Esteva FJ, Kuerer H, Hunt K, McNeese M, Strom E, Buchholz TA, Ames F, Hortobagyi GN. Weekly paclitaxel (P) followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission (PCR) rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol 20:33a, 2001. e-Pub 2001.
60. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault R, Rosales M, Rivera E, Buzdar AU, Frye D, Hortobagyi GN. A detailed evaluation of cariotoxicity: a Phase II study of doxorubicin (D) and paclitaxel (P) for metastatic breast cancer. Proc Am Soc Clin Oncol 20:44a (abstr 173), 2001. e-Pub 2001.
61. Esparza-Guerra L Buzdar A. Anastrozole 'Arimidex' does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 20:52b (abstr 1954), 2001. e-Pub 2001.
62. Sahmoud T, Buzdar A, Smith I, Noguchi S, Jassem J, Dowsett M. The anastrozole (Arimidex) neo-adjuvant breast cancer program. Aromatase 2000 and the 3rd Generation Abstract Book. Port Douglas, Australia, 2000. e-Pub 2000.
63. Buzdar AU. Summary of second line randomized studies of Aromatase inhibitors. Aromatase 2000 and the 3rd Generation Abstract Book. Port Douglas, Australia, 2000. e-Pub 2000.
64. Buzdar AU. New agents in management of metastatic breast cancer. . Taipei International Breast Cancer Symposium: Programme & Abstracts Taipei, Taiwan:43-44, 2000. e-Pub 2000.
65. Buzdar AU. New developments in endocrine therapy for early and advanced breast cancer. Taipei International Breast Cancer Symposium: Programme & Abstracts Taipei, Taiwan:40-42, 2000. e-Pub 2000.
66. Katz A, Buchholz TA, Strom EA, Thames H, Smith CD, Hortobagyi GN, Buzdar A, Theriault, R, Singletary S, McNeese MD. Recursive partitioning analysis (RPA) of locoregional recurrence (LRR) following mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. Proc Am Soc Clin Oncol 19:82a (abstr 313), 2000. e-Pub 2000.
67. Buzdar AU, Hortobagyi GN. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trials. Chemotherapy Foundation Symposium XVIII: Innovative Cancer Therapy for Tomorrow Abstract Book New York, New York:54-55 (abstr 46), 2000. e-Pub 2000.
68. Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, Bonneterre J, von Euler M, Steinberg M, Webster A. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal (Pm) women – combined analysis from two identically designed multicenter trials. Proc Am Soc Clin Oncol 19:154a (abstr 609D), 2000. e-Pub 2000.
69. Asmar L, Ibrahim NK, Buzdar AU, Smith TL, Theriault RL, Hortobagyi GN. Doxorubicin (D) by continuous infusion (CI) vs bolus infusion (BL) in metastatic breast cancer (MBC): impact on time-to-progression (TTP), M.D. Anderson Cancer Center Experience. Proc Am Soc Clin Oncol 19:105a (abstr 406), 2000. e-Pub 2000.
70. Gajewski J, Donato M, Anderlini P, Korbling M, Ueno N, Saliba R, Rondon G, Ippoliti C, Bast R, Buzdar A, Hortobagyi GN, Champlin R. Intensive chemotherapy with G-CSF with mobilization yields improved peripheral blood progenitor (PBPC) collection, quicker recover after high dose chemotherapy (HDC) and reduces progression risk compared to G-CSF alone for mobilization. Proc Am Soc Clin Oncol 19:123a (abstr 477), 2000. e-Pub 2000.
71. Esteva FJ, Hortobagyi GN, Smith TL, Liang S, Pusztai L, Sahin AA, Buzdar AU, Bacus SS. Potential prognostic role of HER-4, heregulin and JNK-P38 in patients with stage II breast cancer treated with doxorubicin-based adjuvant chemotherapy. Proc Am Soc Clin Oncol 19:134a (abstr 526), 2000. e-Pub 2000.
72. Buzdar AU, Boehnke-Michaud L, Hortobagyi GN. What is the optimal duration of chemotherapy in advanced breast cancer? . 10th International Congress on Anti-Cancer Chemotherapy, Paris, France:45 (abstr EL023), 2000. e-Pub 2000.
73. Buzdar AU, Bonneterre J, Nabholtz JM, Robertson JFR, Thurlimann B, von Euler M, Steinberg M, Webster A. Anastrozole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women: Findings highlight the importance of receptor status assessment prior to treatment initiation. Annals of Oncology: Abstract Book of the 25th ESMO Congress 11(4):25 (abstr 990), 2000. e-Pub 2000.
74. Montemurro F, Rondon G, Ueno N, Munsell M, Smith T, Mehra R, Gajewski J, Rahman Z, Buzdar A, Hortobagyi G, Champlin R. Selection of candidates for high dose chemotherapy (HDCT) for metastatic breast cancer (MBC): Importance of the Swenerton score and implications of the “conversion rate”. . Proc Am Soc Clin Onco 19:123a (abstr 476), 2000. e-Pub 2000.
75. Thomas E, Buzdar A, Theriault R, Singletary S, Booser D, Valero V, Ibrahim N, Smith T, Frye D, Manuel N, Kau S, McNeese M. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial. Proc Am Soc Clin Oncol 19:74a (abstr 285), 2000. e-Pub 2000.
76. Trent JC, Valero V, Buzdar AU, Esparza-Guerra LT, Booser DJ, Cristofanilli M, Cl D, Esteva FJ, Murray JL, Rosales MF, Bellet RE, Hortobagyi GN. Phase II study of docetaxel and cyclophosphamide combination chemotherapy as first-line treatment for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 19:108a (abstr 416), 2000. e-Pub 2000.
77. Xiong Q, Valero V, Kau V, Kau S, Mun YJ, Booser DJ, Buzdar AU, Hortobagyi GN, Theriault RL. Breast cancer in women age < 30 years. Proc Am Soc Clin Oncol 19:647a (abstr 2553), 2000. e-Pub 2000.
78. Buzdar AU. Prospective, randomized study of Taxol versus FAC as neoadjuvant therapy in patients with operable breast cancer. New Strategies on the Management of Breast Cancer, Marrakech, Morocco:22, 1999. e-Pub 1999.
79. Buzdar AU. Non-steroidal aromatase inhibitors (AI) in the treatment of breast cancer. Proc 2nd Biennial International Meeting of the Flemish Gynaecological Oncology Group:45, 1999. e-Pub 1999.
80. Buzdar AU. Recent advances in early and advanced breast cancer. . Proc 2nd Biennial Meeting of Asian Breast Cancer Society:13, 1999. e-Pub 1999.
81. Vlastos G, Mirza N, Lenert JF, Binkley SM, Ellis VG, Buzdar AU, Singletary SE. Efficacy of paclitaxel neoadjuvant chemotherapy in tumor downstaging of the axilla in T2-3, N0-1, M0 breast cancer. Proc Am Soc Clin Oncol 18:104a (393), 1999. e-Pub 1999.
82. Chang S, Alderfur J, Asmar L, Buzdar A. Inflammatory breast cancer: The influence of race, menopausal status and body size on survival. Proc Am Soc Clin Oncol 18:616a (asbtr 2380), 1999. e-Pub 1999.
83. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, Buzdar AU, Singletary SE. Feasibility of minimally invasive surgery in stage IIA, IIB, and IIIA breast cancer patients after tumor downstaging with induction chemotherapy. Br Cancer Res and Treatment 57:31 (abstr 451), 1999. e-Pub 1999.
84. Valero V, Buzdar AU, Asmar L, Theriault RL, Booser D, McNeese M, Singletary SE, Hortobagyi GN. Benefits of adjuvant doxorubicin/cyclophosphamide-containing therapy in women with breast cancer by age (<60, 60-69, >69): The University of Texas M. D. Anderson Cancer Center Experience. Proc Am Soc Clin Oncol 18:578a (abstr 2233), 1999. e-Pub 1999.
85. Ueno N, Rondon G, Mehra R, Anderlini P, Donato M, Giralt S, Gajewski J, Braunschweig I, Korbling M, Rahman Z, Buzdar A, Singletary S, Hortobagyi G, Champlin R. High-dose chemotherapy (HDCT) and autologous peripheral blood progenitor cell transplantation (PBPCT) in primary breast cancer refractory to neoadjuvant chemotherapy. Proc Am Soc Clin Oncol 18:104a (abstr 391), 1999. e-Pub 1999.
86. Thomase E, Buzdar AU, Hortobagyi GN, Asmar L, Frye D, Theriault R, Booser D, McNeese M, Strom E, Ames F, Singletary S. Long-term follow up of stage III breast cancer-combined modality treatment with anthracycline containing chemotherapy (CT): The M. D. Anderson Experience. Proc Am Soc Clin Oncol 18:75a (abstr 284), 1999. e-Pub 1999.
87. Rza NQ, Vlastos G, Meric F, Singletary E, Reed L, Ames FC, Feig BW, Ross MI, Pollock RE, Buchholz TA, Strom EA, McNeese MD, Theriault R, Buzdar AU, Hortobagyi GN, Hunt KK. Time to local-regional recurrence (LRR) following breast conserving therapy (BCT) predicts survival. Br Cancer Res and Treatment 57:31 (abstr 160), 1999. e-Pub 1999.
88. Newman LA, Kuerer HM, Hunt KK, Ross MI, Ames FC, Feig BW, Buzdar AU, Fornage B, Singletary SE. Adverse prognostic impact of infraclavicular lymph nodes detected by ultrasound in patients with locally advanced breast cancer (LABC). . Proc Am Soc Clin Oncol 18:71a (abstr 267), 1999. e-Pub 1999.
89. Nabholtz JM, Bonneterre J, Buzdar AU, Thuerlimann BJK, Robertson JFR, Webster A, Steinberg M, von Euler M. Preliminary results of two multi-center trials comparing the efficacy and tolerability of ArimidexÔ (Anastrozole) and Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). . Br Cancer Res and Treatment 57:31 (abstr 27), 1999. e-Pub 1999.
90. Munster P, Buzdar A, Booser D, Theriault R, Frye D, Major M, Dhingra K, Ni L, Norton L, Hudis C. Pharmacodynamics and pharmakokinetics of LY353381.HCI, a selective estrogen receptor modulator (SERM), in women (pts) with refractory, metastatic breast cancer (MBC). . Proc Am Soc Clin Oncol 18:110a (abstr 414), 1999. e-Pub 1999.
91. Buzdar AU, Hortobagyi GN, Theriault RL, Booser DJ, Valero VV, Ibrahim NI, Asmar L, Frye D, Manuel N, Kau S, McNeese M, Strom E, Hunt K, Singletary E, Ames F. Prospective randomized trial of taxol (Tax) alone versus fluorouracil, doxorubicin, cyclophosphamide with operable breast cancer (Br Ca). Proc Am Soc Clin Oncol 18:73a (abstr 273), 1999. e-Pub 1999.
92. Dhingra K, Esparza-Guerra L, Valero V, Booser D, Theriault R, Singletary E, Strom E, McNeese M, Buzdar A, Sahin A, Hunt K, Martinez N, Hortobagyi G. A phase III randomized trial of dose-intensive, neoadjuvant breast cancer (LABC)-efficacy and safety data. Proc Am Soc Clin Oncol 18:74a (abstr 278), 1999. e-Pub 1999.
93. Gajewski J, Donato M, Anderlini P, Korbling M, Khouri I, Rondon G, Giralt S, Buzdar A, Ueno N, Andersson B, Durrett A, Saliba R, Bruton J, Molldrem J, Ippoliti C, Raber M, Bast R, Hortobagyi G, Champlin R. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to growth factor alone for hematopoietic rescue after high dose chemotherapy (HDC). Proc Am Soc Clin Oncol 18:50a (abstr 187), 1999. e-Pub 1999.

Book Chapters

1. Buzdar AU, Dawood S, Harvey HA, Jordan VC. Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. In: Holland-Frei Cancer Medicine. 9th. John Wiley & Sons, Inc, 713-732, 2017.
2. Buzdar AU, Buchholz TA, Taylor SH, Hortobagyi GN, Hunt KK. Breast Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, 19-34, 2013.
3. Buzdar AU, Dawood S, Harvey HA, Jordan VC. Antiestrogens, Progestins, and Aromatase Inhibitors. In: Cancer Medicine. 8th. BC Decker, 737-749, 2010.
4. Buzdar AU. The third-generation aromatase inhibitors: a clinical overview. In: Aromatase Inhibitors. 2. Birkhauser, 2008.
5. Buzdar AU, Harvey HA, Jordan VC. Chapter 54: Estrogen, Antiestrogens, and Aromastase Inhibitors. In: Cancer Medicine. BC Decker Inc, 828-842, 2006.
6. Buzdar AU. Chapter 21: Endocrine therapy of early and advanced breast cancer. In: Breast Cancer. 2nd Ed. BC Decker Inc, 331-352, 2006.
7. Fanale MA, Buzdar AU. Chapter 19: Early-stage, locally advanced, and inflammatory breast cancer. In: MD Anderson Manual of Medical Oncology. McGraw-Hill Company, 463-502, 2006.
8. Berry DA, Smith TL, Buzdar AU. Breast Cancer. In: Textbook of Clinical Trials. 2. John Wiley & Sons, Ltd, 49-62, 2006.
9. Buzdar AU. The third-generation aromatase inhibitors: a clinical overview. In: Aromatase Inhibitors. Birkhauser Veralg, 119-137, 2005.
10. Buzdar AU. Chapter 57: Endocrine therapy for metastatic breast cancer. In: Advanced Therapy of Breast Disease. BC Decker Inc, 567-578, 2004.
11. Buzdar AU, Gradishar WJ. Chapter 45: Adjuvant hormonal therapy for early breast cancer in postmenopausal women. In: Advanced Therapy of Breast Disease. BC Decker Inc, 459-466, 2004.
12. Singletary SE, Buzdar AU. Breast Cancer: Adjuvant Systemic Therapy. In: Current Surgical Therapy. Elsevier Mosby Inc, 641-645, 2004.
13. Whitman GJ, Iyer RB, Lifshitz OH, Buzdar AU. Chapter 10: Sequential magnetic resonance and response of breast cancer to neoadjuvant therapy. In: Image-Guided Diagnosis and Treatment of Cancer. Humana Press Inc, 213-228, 2003.
14. Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. In: Surg Clin N Am, 973-994, 2003.
15. Baum M, Buzdar A. Chapter 7: Anastrozole as adjuvant therapy. In: History and Advancement of Anastrozole in the Treatment of Breast Cancer. Royal Society of Medicine Press Ltd, 45-51, 2003.
16. Buzdar AU, Harvey HA. Chapter 64: Aromatase Inhibitors. In: Cancer Medicine. BC Decker Inc, 947-959, 2003.
17. Boehnke Michaud L, Wojdylo JR, Buzdar AU. Chapter 6: Novel hormonal agents. In: Breast Cancer Therapy Annual. Martin Dunitz, 91-106, 2003.
18. Jones KL, Buzdar AU, Hortobagyi GN. Chapter 15: Aromatase inhibitors in the treatment of breast cancer. In: Breast Cancer Management: Application of Clinical and Translational Evidence to Patient Care. Lippincott Williams & Wilkins, 203-222, 2002.
19. Strom EA, Buzdar AU, Hunt KK. Chapter 1: Multidisciplinary Care of the Breast Cancer Patients: Overview and Implementation. In: Breast Cancer. Springer-Verlag, 1-19, 2001.
20. Buzdar AU. Chapter 13: Endocrine Therapy for Breast Cancer. In: Breast Cancer. Springer-Verlag, 366-381, 2001.
21. Blumenschein GR, Buzdar AU, Hortobagyi GN. FAC+BCG as adjuvant therapy in breast cancer: An 8 year Update. In: Recent Results of Cancer Research, 129-132, 2000.
22. Hortobagyi GN, Buzdar A. Preoperative (Neoadjuvant) Chemotherapy for Operable Breast Cancer. In: Textbook of Breast Cancer: A Clinical Guide to Therapy. Martin Dunitz Ltd, 119-137, 2000.
23. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. In: Breast Cancer Management. Adis International, 21-33, 2000.
24. Buzdar AU, Hortobagyi GN. Aromatase Inhibitors in the Treatment of Breast Cancer. In: Breast Cancer Management: Application of Evidence to Patient Care. Martin Dunitz Ltd, 171-180, 2000.
25. Buzdar AU, Hortobagyi GN. New Endocrine Agents in Breast Cancer. In: Textbook of Breast Cancer: A Clinical Guide to Therapy. Martin Dunitz Ltd, 251-262, 2000.
26. Buzdar AU, Diamandidou E. Aspetti Clinici. In: Carcinoma della Mammella. Poletto Editore, 61-70, 1999.
27. Buzdar AU, Cristofanilli M. Terapia Endocrina. In: Carcinoma della Mammella. Potello Editore, 307-320, 1999.
28. Buzdar AU, Cristofanilli M, Pro B. Manifestazioni Del Sistem Nervoso Centrale. In: Carcinoma della Mammella. Potello Editore, 347-352, 1999.
29. Singletary SE, Buzdar AU. Inflammatory breast cancer. In: Breast Cancer. Blackwell Science, Inc, 139-174, 1999.
30. Buzdar AU, Brunelli CA, Zwelling LA. Protecting human subjects from risk in the performance of clinical research and the informed consent process. In: Progress in Anti-Cancer Chemotherapy. Springer-Verlag, 7-20, 1999.
31. Buzdar AU, Cristofanilli M, Hortobagyi G. Carcinoma Infiammatorio. In: Carcinoma della Mammella. Potello Editore, 296-306, 1999.
32. Buzdar AU, Hortobagyi GN. Breast Cancer. In: Cancer Chemotherapy and Biological Response Modifies Annual 18. Elsevier Sciences B.V, 435-469, 1999.
33. Singletary SE, Buzdar AU, Diamandidou E. Advanced breast carcinoma, locoregional recurrences, and distant metastases. In: Breast Cancer. Blackwell Science, Inc, 118-138, 1999.
34. Buzdar AU, Cristofanilli M, Pro B. Fractture Patologiche. In: Carcinoma della Mammella. Potello Editore, 353-355, 1999.
35. Buzdar AU, Matei CM. Quimioterapia primaria en cancer mamario. In: Compendio de Patologia Mamaria. Academia Mexicana de Cirugia, 207-216, 1999.
36. Thomas E, Buzdar AU, Hortobagyi GN, Asmar L, Frye D, Theriault R, Booser D, McNeese M, Strom E, Ames F, Singletary SE. Treatment of locally advanced and inflammatory breast cancer. In: Advanced Therapy of Breast Disease. B.C. Decker, Inc, 267-280, 1999.
37. Hortobagyi GN, Buzdar AU. Treatment of metastatic breast cancer. In: Advanced Therapy of Breast Diseases. B.C. Decker, Inc, 281-289, 1999.
38. Hunt KK, Buzdar AU. Breast conservation after tumor downstaging with induction chemotherapy. In: Breast Cancer, M. D. Anderson Solid Tumor Oncology Series. Springer-Verlag, 196-207, 1998.
39. Singletary SE, Buzdar AU. Inflammatory breast cancer. In: Cancer in Women. Blackwell Science, Inc, 195-203, 1998.
40. Singletary SE, Buzdar AU, Diamandidou E. Advanced breast carcinoma, locoregional recurrences, and distant metastases. In: Cancer in Women. Blackwell Science, Inc, 174-194, 1998.
41. Diamandidou E, Buzdar AU, Plourde P. Breast Cancer. In: Drug Development for Women. John Wiley and Sons Publishers, 337-386, 1998.
42. Friedewald V, Buzdar AU. . In: Ask the Doctor: Breast Cancer. Andrews and McMeel, 1997.
43. Hortobagyi GN, Buzdar AU. Locally Advanced Breast Cancer. In: Textbook of Breast Cancer - A Clinical Guide to Therapy. Martin Dunitz Publishers, 155-168, 1997.
44. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined mocality treatment of stage III and inflammatory breast cancer. In: Management Strategies for the Care of Advanced Primary and Metastatic Breast Cancer. W. B. Saunders Co, 715-734, 1995.
45. Holmes FA, Valero V, Walters R, Theriault R, Booser D, Buzdar A, Gibbs H, Frye D, Young K, Hortobagyi G. Taxol in metastatic breast cancer: the M. D. Anderson Cancer Center Experience. In: Cancer Treatment -An Update. Springer-Verlag, 161-171, 1994.
46. Buzdar AU, Hortobagyi G, Kau S, Holmes F, Fraschini G, Theriault R, McNeese M, Singletary S. Long-term efficacy and late sequelae of doxorubicin-containing adjuvant therapy for breast cancer: M. D. Anderson Cancer Center Studies. In: Cancer Treatment - An Update. Springer-Verlag, 163-166, 1994.
47. Hortobagyi GN, Buzdar AU, Frye D, Singletary SE, Holmes FA, Ames F, McNeese MD, Theriault RL. Primary chemotherapy for breast cancer: Response to preoperative chemotherapy as prognostic factor. In: Cancer Treatment - An update. Springer-Verlag, 105-109, 1994.
48. Buzdar AU, Hortobagyi GN, Holmes FA, McNeese M, Theriault RL, Singletary SE. M. D. Anderson Cancer Center Adjuvant Therapy Trials in Stage II or III breast cancer. In: Proceedings of teh Seventh International Symposium, Arlington, TX, Autologous Marrow and Blood Transplantation VII. Baxter Healthcare Corporation - Hyland Division, 169-173, 1994.
49. Galindo EG, Buzdar AU. Avaliação de Pacientes em Seguimento Após Tratamento. In: CÂNCER DA MAMA Diagnóstico e Tratamento. Medsi, 197-204, 1994.
50. Dhingra K, Fritsche H, Murray JL, LoBuglio A, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A, Raber M, Gutierrez L, Hortobagyi G. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by Deoxyspergualin: A Phase I Study. In: Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, 193-202, 1994.
51. Buzdar AU, Frye D, Ho D, Booser D, Valero V, Holmes FA, Plourde P, Hortobagyi GN. Bioavailability of Nolvadex (Tamoxifen Citrate) as Once-Daily and Twice Daily Dosage Regimens in Patients with Breast Cancer. In: Adjuvant Therapy of Cancer VII. J. B. Lippincott Co, 237-239, 1993.
52. Buzdar AU, Hortobagyi GN, Kau SW, Holmes FA, Fraschini G, Theriault RL, McNeese M, Ross M, Singletary E. Breast cancer adjuvant therapy at the M. D. Anderson Cancer Center - Results of four prospective studies. In: Adjuvant Therapy of Cancer VII. J. B. Lippincott Co, 220-225, 1993.
53. Hughes P, Buzdar A. Early stage breast cancer and adjuvant therapy. In: Medical Oncology: A Comprehensive Review, University of Texas M. D. Anderson Cancer and the journal Oncology, 201-208, 1993.
54. Dunphy F, Spitzer G, Yau J, Huan S, Spinolo J, Jagannath S, Wallerstein R, Dicke K, Buzdar A, Hortobagyi G. Long-term follow-up of poor prognosis stage IV breast cancer patients treated with two courses of high-dose chemotherapy and bone marrow support. In: Sixth International Symposium on Autologous Bone Marrow Transplantation VI, 118-123, 1993.
55. Giralt S, Buzdar AU. Progestins and other pregnane derivatives. In: Antitumor Steroids. Academic Press, Inc, 123-153, 1992.
56. Spitzer G, Huan S, Dunphy FR, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagganath JS, Holmes FA, Wallerstein RO, Dicke KA. Tandem high dose chemotherapy for metastatic breast cancer. In: Autologous Bone Marrow Transplantation V. The U. of Nebraska Medical Center, 323-332, 1991.
57. Hortobagyi GN, Buzdar AU. Locally advanced breast cancer: A review including the M.D. Anderson Experience. In: High Risk Breast Cancer Therapy. Springer-Verlag, 382-416, 1991.
58. Spitzer G, Huan S, Dunphy F, Dicke K, Wallerstein R, Hortobagyi G, Buzdar A, Holmes F, Yau J, Deisseroth A. Double high-dose therapy in human solid tumors an emphasis on breast cancer. . In: New Strategies in Bone Marrow Transplantation, 437-445, 1991.
59. Hortobagyi GN, Ames FC, Buzdar AU, Kau S, Frye D, McNeese MD, Holmes FA, Fraschini G, Hug V, McBride CM. Combined modality therapy for locally advanced breast cancer: 14 years results. In: Adjuvant Therapy of Cancer VI. W.B. Saunders Co, 254-261, 1990.
60. Buzdar AU, Hortobagyi GN, Kau S, Smith TL, Fraschini G, Holmes FA, Hug V, Gutterman JU, McNeese MD, Singletary SE, Ames F. Doxorubicin-containing adjuvant therapy for patients with stage II breast cancer: M. D. Anderson Cancer Center Experience. In: Adjuvant Therapy of Cancer VI. W.B. Saunders Co, 210-215, 1990.
61. Hortobagyi GN, Dunphy F, Buzdar A, Spitzer G. Dose intensity studies in breast cancer - Autologous bone marrow transplantation. In: Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part B: Clinical Aspects. Wiley-Liss, 195-209, 1990.
62. Ang PT, Buzdar AU. Breast Cancer. In: Difficult Medical Management. W. B. Saunders Co, 126-131, 1990.
63. Holmes FA, Buzdar AU, Kau S, Fraschini G, Hug V, Smith T, Theriault TL, Singletary ES, Ames F, McNeese MD, Hortobagyi GN. Isolated Visceral Recurrences of Breast Cancer: 10 Year Results of a Combined Modality Approach. In: Adjuvant Therapy of Cancer VI. W.B. Saunders Co, 262-266, 1990.
64. Dunphy FR, Spitzer G, Ellis JK, Dicke KA, Buzdar AU, Hortobagyi GN. Autologous bone marrow transplantation and hematopoietic recovery in solid tumors. In: Autologous Bone Marrow Transplantation, Proceedings of the Fourth International Symposium. The University of Texas M. D. Anderson Cancer Center, 405-410, 1989.
65. Buzdar A, Hortobagyi G, Kau S, Patel H, Hug V, Holmes G, Fraschini G, Singletary S, Ames F. Evaluation of risk and benefits of doxorubicin-containing (FAC) adjuvant chemotherapy in breast cancer - M. D. Anderson Cancer Center Experience. In: Proceedings of the 16th International Congress of Chemotherapy, June, 781.1-781.2, 1989.
66. Spitzer G, Dunphy FR, Ellis JK, Buzdar AU, Hortobagyi GN, Holmes FA, Jabboury KW, Horwitz LJ, Jagannath S, Dicke KA. High-dose intensification for stage IV hormonally-refractory breast cancer. In: Autologous Bone Marrow Transplantation, Proceedings of the Fourth International Symposium. The University of Texas M.D. Anderson Cancer Center, 399-404, 1989.
67. Buzdar AU. What is Best for the Patient? A United States View. In: Cost Versus Benefit in Cancer Care. The MacMillan Press LTD, 19-30, 1988.
68. Hortobagyi GN, Buzdar AU, Ames FC, McNeese MD. Neo-adjuvant chemotherapy in the management of advanced primary carcinoma of the breast. In: Neo-Adjuvant Chemotherapy. Colloque INSERM/John Libbey Eurotext Ltd, 137-142, 1988.
69. Dunphy FR, Spitzer G, Dicke KA, Buzdar AU, Hortobagyi GN. Tandem high-dose chemotherapy as intensification in stage IV breast cancer. In: Bone Marrow Transplantation: Current Controversies, UCLA Symposia on Molecular and Cellular Biology, New Series, V 87. Alan R. Liss, Inc, 245-251, 1988.
70. Buzdar AU. Progestins in Cancer Treatment. In: Endocrine Management of Cancer, 2 Contemporary Therapy. S. Karger, 1-15, 1988.
71. Buzdar AU. Diseases of the Breast - A book review. In: The Cancer Bulletin, 67, 1987.
72. Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Hug V, Campos LT, Ames FC, Martin RG. Breast cancer adjuvant therapy trials of M. D. Anderson Hospital: Results of three studies. In: Proceedings of the Fifth International Conference, Adjuvant Therapy of Cancer V. Grune & Stratton, 411-418, 1987.
73. Hortobagyi GN, Kau S, Buzdar AU, Ames F, McNeese M, Frye D, Holmes F, Fraschini G, Hug V, Martin R, Montague E. Induction chemotherapy for stage III primary breast cancer. In: Proceedings of the Fifth International Conference, Adjuvant Therapy of Cancer V. Grune & Stratton, 419-428, 1987.
74. Hortobagyi GN, Buzdar AU, Montague E, Romsdahl M. Neo-adjuvant chemotherapy for primary breast cancer. In: Colloque INSERM/John Libbey Eurotext Ltd, 189-196, 1986.
75. Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR, Montague ED. Induction chemotherapy of breast cancer. In: Primary Chemotherapy in Cancer Medicine. Alan R. Liss, Inc, 105-116, 1985.
76. Buzdar A, Smith T, Blumenschein G, Hortobagyi G. Adjuvant chemotherapy of operable breast cancer with doxorubicin-containing regimen. In: Results of Three Trials at M. D. Anderson Hospital, Proc. of the 14th International Congress of Chemotherapy, Kyoto, 703-704, 1985.
77. Blumenschein GR, Yap HY, Hortobagyi GN, Buzdar AU, Issell, BF. The role of VP-16 (etoposide) in the treatment of metastatic breast cancer. In: Etoposide (VP-16-213): Current Status and New Developments. Academic Press, 253-260, 1984.
78. Moon TE, Jones SE, Tong T, Serokman R, Bonadonna G, Veronesi U, Powles TJ, Buzdar AU, Montague E. Development of a natural history data base of breast cancer studies. In: Adjuvant Therapy of Cancer IV, Proc of Fourth International Conference, 227-233, 1984.
79. Hortobagyi GN, Smith TL, Blumenschein GR, Legha SS, Yap HY, Buzdar AU. Clinical prognostic factors of response. In: Current Controversies in Breast Cancer. University of Texas Press, 255-259, 1984.
80. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi GN, Marcus CE, Hersh E, Martin RG, Gehan EA, Freireich EJ. Breast cancer adjuvant therapy trials of M. D. Anderson Hospital: Results of two studies. In: Adjuvant Therapy of Cancer IV, Proc. of Fourth International Conference, 217-225, 1984.
81. Buzdar AU, Smith TL, Marcus C, Hortobagyi G, Blumenschein G. Significance of drug, dose, timing and radiotherapy in adjuvant therapy of breast cancer. In: 2nd International on Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research, 141-147, 1984.
82. Gehan EA, Smith TL, Buzdar AU. Statistical considerations for historical controlled adjuvant studies with application to FAC-BCG study in breast cancer. In: Current Controversies in Breast Cancer, 469-476, 1984.
83. Jones S, Moon T, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T. The use of a natural history data base (NHDB) to compare selected adjuvant trials or women with operable stage II (node positive) breast cancer. In: Adjuvant Therapy of Cancer IV, Proc of Fourth International Conference on Adjuvant Therapy, 1984.
84. Hortobagyi GN, Fritsche HA, Mughal AW, Buzdar AU, Yap HY, Blumenschein GR. Role of carcinoembryonic antigen for follow-up of breast cancer patients. In: Current Controversies in Breast Cancer. University of Texas Press, 461-465, 1984.
85. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. In: New Perspectives in Chemotherapy: Focus on Novantrone, Seminars in Oncology XI, 28-31, 1984.
86. Yap HY, Buzdar AU, Hortobagyi GN, Blumenschein G, Bodey G. Promising new agents for metastatic breast cancer. In: 26th Annual Clinical Conference - Current Controversies in Breast Cancer. University of Texas Press, 283-290, 1984.
87. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi GN, Yap HY, Hersh EM, Gehan EA. Adjuvant therapy for stage II or III breast cancer: U.T. M. D. Anderson Hospital Experience. In: Current Controversies in Breast Cancer, 169-182, 1984.
88. Blumenschein GR, Pinnamaneni K, Buzdar AU, Hortobagyi GN, Yap HY, Montague ED, Ames FC. Combined regional and systemic therapy in breast cancer patients with an isolated metastasis with or without prior chemotherapy. In: Adjuvant Therapy of Cancer IV, Proc. of Fourth International Conference on Adjuvant Therapy, 311-320, 1984.
89. Blumenschein GR, Buzdar AU, Yap HY, Hortobagyi GN. Seven year follow-up of stage IV patients entering complete remission from FAC. In: Proc. 13th International Congress of Chemotherapy, Vienna, Austria, August 28-Sept. 2, 244/9, 1983.
90. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. In: Proc of IABS Symposium on BCG & Tuberculins, Budapest, September 6 to 9, 1983.
91. Buzdar AU, Ross M, Smith T, Blumenschein G, Hortobagyi G, Eckles N, Gehan E, Freireich E. Improved survival in metastatic breast cancer treated with combination chemotherapy - an experience of past 3 decades. In: Proc 13th International Congress of Chemotherapy, Vienna, Austria, August 28-Sept. 2, 244/1, 1983.
92. Buzdar AU, Blumenschein GR, Hortobagyi GN, Legha SS, Yap HY, Campos LT, Hersh EM. Adjuvant chemotherapy with 5-fluorouracil, adriamycin and cyclophosphamide, with or without BCG immunotherapy in stage II or III breast cancer. In: Proc. II International Conference on Immunotherapy of Cancer. Cancer Sec. IV, 175-181, 1982.
93. Hortobagyi GN, Blumenschein GR, Buzdar AU, Yap HY. Combination chemotherapy for metastatic breast cancer. In: Proc. of the Symposium on Chemotherapy for metastatic breast cancer. (part 2). Adria Laboratories, Inc, 12-16, 1982.
94. Blumenschein GR, Hortobagyi GN, Buzdar AU, Yap HY. Poor prognosis breast cancer - is cure possible?. In: Education distribution by the CICA Satellite Committee, presented at CANCER 1981 Cancer 2001: In Proceedings II International Conference on Immunology of Cancer, Cancer (Sect. IV), 175-181, 1982.
95. Bodey G, Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU. A randomized comparative study of vinblastine, vindesine and vincristine in patients with refractory metastatic breast cancer. In: Drugs Under Experimental and Clinical Research, 559-563, 1982.
96. Blumenschein GR, Yap HY, Hortobagyi GN, Buzdar AU, Legha SS. Interaction between vinca alkaloids in breast carcinoma. In: Proc. of the 12th Intl. Congress of Chemotherapy, Florence, Italy, July 19-24, 19-24, 1981.
97. Fraschini G, DiStefano A, Yap HY, Barnes BC, Buzdar AU, Hortobagyi GN, Blumenschein GR. Chemotherapy with dibromodulcitol, Adriamycin, cyclophosphamide for metastatic breast cancer. In: Current Chemotherapy and Immunotherapy; Proceedings of the XII International Congress of Chemotherapy, Washington, D.C., American Association of Microbiology, 1485-1487, 1981.
98. Buzdar AU, Powell KC, Legha SS, Hortobagyi GN, Blumenschein GR. Trioxifene mesylate in the treatment of advanced breast cancer - A phase I-II study. In: In Current Chemotherapy and Immunotherapy; Proc. 12th Intl. Congress of chemotherapy, Florence, Italy, July 19-24, Washington, D.C., American Association of Microbiology, 1472-1473, 1981.
99. Blumenschein GR, Buzdar AU, Hortobagyi GN, Yap HY. Adjuvant chemo-immunotherapy to regionally treated stage IV breast cancer patients - a five year follow-up. In: Adjuvant Therapy of Cancer III, 427-434, 1981.
100. Buzdar AU, Smith TL, Blumenschein GR, Hortobagyi GN, Hersh EM, Gehan E. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) for stage II or III breast cancer: 5 year results. In: Adjuvant Therapy of Cancer III, 419-426, 1981.
101. Blumenschein GR, Hortobagyi GN, Buzdar AU, DiStefano A, Gutterman J, Hersh EM. Review of multiple non-specific immunotherapeutic agents in combination with FAC chemotherapy of stage IV breast cancer. In: Tumor Regression. North Holland, Inc, 369-378, 1980.
102. Blumenschein GR, Buzdar AU, Hortobagyi GN, Tashima CK. Adjuvant chemoimmunotherapy following regional therapy for initial solitary metastases of breast cancer (stage IV NED). In: Adjuvant Therapy of Cancer II. Grune & Stratton, 303-310, 1979.
103. Buzdar AU, Gutterman JU, Blumenschein GR, Tashima CK, Hortobagyi GN, Yap HY, Hersh EM, Gehan EA. Adjuvant therapy of stage II, III breast cancer. In: Recent Results in Cancer Research. Springer-Verlag, 123-128, 1979.
104. Buzdar AU, Blumenschein GR, Gutterman JU, Hortobagyi GN, Campos LT, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Adjuvant therapy with 5-fluorouracil, adriamycin, cyclophosphamide and BCG (FAC-BCG) for stage II or III breast cancer. In: Adjuvant Therapy of Cancer II. Grune & Stratton, 277-284, 1979.
105. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar AU, Burgess MA, Richman SP, Tashima CK, Schwartz M, Hersh EM. Chemoimmunotherapy of advanced breast cancer with BCG. In: Progress in Cancer Research and Therapy, vol. 6, Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, 655-668, 1978.
106. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar AU, Tashima CK, Richman SP, Wiseman CL, Yap HY, Hersh EM. Immunotherapy and chemoimmunotherapy of human breast cancer. In: Immunotherapy of Human Cancer. Raven Press, 321-345, 1978.
107. Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Buzdar AU, Hersh EM. Levamisole in treatment of breast cancer. In: Immune Modulation and Control of Neoplasia by Adjuvant Therapy. Raven Press, 131-140, 1978.
108. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar AU, Hersh EM. Chemoimmunotherapy of advanced breast cancer with BCG. In: Recent Results in Cancer Research. Springer-Verlag, 143-150, 1977.
109. Blumenschein GR, Buzdar AU, Hortobagyi GN, Gutterman JU, Tashima CK. Non-specific active immunotherapy in combination with chemotherapy for the treatment of metastatic breast cancer. In: Neoplasm Immunity: Solid Tumor Therapy. Franklin Inst. Press, 169-177, 1977.
110. Blumenschein GR, Buzdar AU, Tashima CK, Hortobagyi GN. Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer. In: Adjuvant Therapy of Cancer. North-Holland Publishing Co, 147-152, 1977.
111. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Wheeler W, Gehan E, Freireich E, Hersh EM. Adjuvant chemoimmunotherapy following regional therapy in breast cancer. In: Adjuvant Therapy of Cancer. North-Amsterdam: North-Holland Publishing Co, 139-146, 1977.
112. Hortobagyi GN, Gutterman JU, Blumenschein GR, Buzdar AU, Hersh EM. Levamisole in the treatment of breast cancer. In: Immune Modulation and Control of Neoplasia by Adjuvant Therapy, M.A. Chirigos. Raven Press, 131-140, 1976.

Books (edited and written)

1. Manzullo EF, Gonzalez CE, Escalante CP, Yeung SJ. Oncologic Emergencies. Springer Science+Business Media, 2016.
2. Foxhall LE, Rodriguez MA. Advances in Cancer Survivorship Management. Springer Science+Business Media, 2015.
3. Lin PP, Patel S. Bone Sarcoma. Springer Science+Business Media, 2013.
4. DeMonte F, Gilbert MR, Mahajan A, McCutcheon IE. Tumors of the Brain and Spine. Springer Science+Media, LLC, 2007.
5. Buzdar AU. Endocrine Therapies in Breast Cancer. Oxford Oncology Library, 2007.
6. Eifel PJ, Gershenson DM, Kavanagh JJ, Silva EG. Gynecologic Cancer. Springer Science+Business Media Inc, 2006.
7. Ajani JA, Curley SA, Janjan NA, Lynch PM. Gastrointestinal Cancer. Springer-Verlag, 2005.
8. Chan KW, Raney RB. Pediatric Oncology. Springer-Verlag, 2005.
9. Buzdar A, Baum M. History and Advancement of Anastrozole in the Treatment of Breast Cancer. Royal Society of Medicine Press Ltd, 2003.
10. Tonkin K, Reese DM, Aapro MS, Buzdar AU. Breast Cancer Management: Application of Clinical and Translational Evidence to Patient Care. Lippincott Williams & Wilkins, 2002.
11. Fossella FV, Komaki R, Putnam JB. Lung Cancer. Springer-Verlag, 2002.
12. Hunt KK, Robb GL, Strom EA, Ueno NT. Breast Cancer. Springer-Verlag, 2001.
13. Nabholtz JM, Tonkin K, Aapro MS, Buzdar AU. Breast Cancer Management: Application of Evidence to Patient Care. Martin Dunitz Ltd, 2000.
14. Bonifacino A, Halliwell M, Buzdar AU. Carcinoma della Mammella. Poletto Editore, 1999.

Letters to the Editor

1. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, investigators A. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135-41, 2010.
2. Buzdar AU, Baum M, Cuzick J. Letrozole or tamoxifen in early breat cancer. New England Journal of Medicine 354(14): 1528-30, 2006.
3. Buzdar AU. St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy. Ann Oncol 17(5): 878-9, 2006.
4. Buzdar AU. Letrozole in breast cancer. N Engl J Med 350: 727-730, 2004.
5. Buzdar AU. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. JCO 22: 3199-3200, 2004.
6. Cuziek J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant use of anastrozole in breast cancer. JCO 22: 1524-1533, 2004.
7. Baum M, Buzdar A, Howell A. ATAC trial did not report interim results. BMJ 327: 1050, 2003.
8. Buzdar AU, Mouridsen H, Chaudri-Ross HA. Superior efficacy of letrozole versus tamoxifen as first-line therapy. J Clin Oncol 20: 876-882, 2002.
9. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thurlimann B, Steinberg M, Webster A, von Euler M. Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer? . Journal of Clinical Oncology 19: 2578-2582, 2001.
10. Mackey JR, Joy AA, Buzdar AU, Brady C, Chaudri-Ross HA. Letrozole in Second-Line Therapy of Advanced Breast Cancer: More Questions Than Answers. J Clin Oncol 19: 4353-4355, 2001.
11. Buzdar AU. Letrozole: Which Dose to be Used? . J Clin Oncol 18: 1802-1803, 2000.
12. Buzdar AU, Hortobagyi GN. Tamoxifen and Toremifene in Breast Cancer: Comparison of Safety and Efficacy - Author’s Response. J Clin Oncol 16: 1999-2000, 1998.
13. Valero V, Buzdar AU, Hortobagyi GN. Regarding: Valero V, Buzdar AU, Hortobagyi GN: Locally Advanced Breast Cancer - Author’s Response . The Oncologist 1: 278-279, 1996.
14. Jaiyesimi IA, Buzdar AU, Ross MA. Carcinoma of the male breast. Ann Int Med 118: 749, 1993.
15. Buzdar AU, Hortobagyi GN. Sixteen-Week, Dose-Intense Chemotherapy in Adjuvant Treatment of Breast Cancer. JNCI 82: 1220, 1990.
16. Buzdar AU, Ellerbroek NA, Libshitz HI. Osteolysis of the Clavicle. Jama 260: 3129, 1988.
17. Buzdar AU, Hortobagyi GN. Adjuvant therapy for breast cancer. Jama 255: 2296, 1986.
18. Hortobagyi GN, Buzdar AU. Progress in inflammatory breast cancer: Cause for cautious optimism. J Clin Oncol 4: 1727-1729, 1986.
19. Buzdar AU, Hortobagyi GN. Long-term tamoxifen adjuvant therapy in node positive breast cancer. Breast Cancer Res Treat 6: 149-150, 1985.
20. Buzdar AU, Fraschini G, Blumenschein GR. Hematologic adverse effects of aminoglutethimide. Ann Intern Med 100: 159, 1984.
21. Buzdar AU, Smith T, Blumenschein GR. Adjuvant chemotherapy for early breast cancer. Br Med J 287: 1141, 1983.
22. Krutchik AN, Buzdar AU, Tashima CK, Blumenschein GR. Endobronchial metastases in breast cancer. Chest 74: 319-320, 1980.
23. Legha SS, Blumenschein GR, Buzdar AU, Hortobagyi GN. Hormone receptors in breast cancer and response to chemotherapy. N Engl J Med 300: 1053, 1979.
24. Buzdar AU, Legha SS, Hortobagyi GN, Blumenschein GR. Drug-associated cardiotoxicity. Jama 241: 1893, 1979.
25. DiStefano AD, Buzdar AU. Viral-induced remission in chronic lymphocytic leukemia?. Arch Intern Med 39: 946, 1979.
26. Krutchik AN, Tashima CK, Buzdar AU, Blumenschein GR. Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. Arch Intern Med 138: 1302-1303, 1978.
27. Krutchik AN, Buzdar AU. Liver metastases vs. granulomas: A caveat. Ann Intern Med 88: 844-845, 1978.
28. Krutchik AN, Buzdar AU. Liver scanning in breast cancer. Arch Surg 113: 1110, 1978.
29. Krutchik AN, Buzdar AU, Tashima CK. Azathioprine and breast carcinoma. Jama 239: 107, 1978.
30. Buzdar AU, Eckles N, Tashima CK. Estrogen therapy and metastatic breast cancer. Jama, 1977.